[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 58 of about 58
1. Di Ieva A, Grizzi F, Gaetani P, Goglia U, Tschabitscher M, Mortini P, Rodriguez y Baena R: Euclidean and fractal geometry of microvascular networks in normal and neoplastic pituitary tissue. Neurosurg Rev; 2008 Jul;31(3):271-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This physical characteristic and the highly variable shapes of the vessels lead to considerable spatial and temporal heterogeneity in the delivery of oxygen, nutrients and drugs, and the removal of metabolites.
  • Although these biological characteristics are well known, quantitative analyses of newly formed vessels in two-dimensional histological sections still fail to view their architecture as a non-Euclidean geometrical entity, thus leading to errors in visual interpretation and discordant results from different laboratories concerning the same tumour.
  • [MeSH-major] Fractals. Pituitary Gland / anatomy & histology. Pituitary Gland / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):883-93 [12072542.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1441-5 [10780524.001]
  • [Cites] Eur J Morphol. 2005 Oct-Dec;42(4-5):217-24 [16982479.001]
  • [Cites] J Pathol. 1995 Nov;177(3):275-83 [8551390.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12 [7563203.001]
  • [Cites] Endocr Pathol. 1997 Autumn;8(3):189-193 [12114722.001]
  • [Cites] Microvasc Res. 1996 May;51(3):327-46 [8992232.001]
  • [Cites] J Appl Physiol (1985). 2005 Mar;98(3):850-5 [15542575.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):533-7 [11297244.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2506-12 [9059340.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1159-62 [10720055.001]
  • [Cites] Folia Histochem Cytobiol. 2001;39 Suppl 2:75-6 [11820635.001]
  • [Cites] Neuroendocrinology. 1986;43(2):159-65 [3523276.001]
  • [Cites] Eur J Cancer. 2002 Aug;38(12):1564-79 [12142044.001]
  • [Cites] Endocr Pathol. 2000 Autumn;11(3):215-227 [12114694.001]
  • [Cites] Curr Eye Res. 1993 Jan;12(1):23-7 [8436007.001]
  • [Cites] J Pediatr. 2006 Jan;148(1):132-7 [16423614.001]
  • [Cites] Endocr Pathol. 2000 Winter;11(4):341-352 [12114758.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [Cites] Am J Surg Pathol. 1980 Jun;4(3):273-6 [6772042.001]
  • [Cites] J Pathol. 1993 Aug;170(4):479-84 [8410497.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):71-6 [16078111.001]
  • [Cites] BMC Cancer. 2005 Feb 08;5:14 [15701176.001]
  • [Cites] J Cell Biol. 1991 Sep;114(5):1059-68 [1874786.001]
  • [Cites] Am J Pathol. 1972 Apr;67(1):109-26 [5055626.001]
  • [Cites] J Theor Biol. 1998 Dec 21;195(4):525-32 [9837706.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):174-82 [8685210.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):239-47 [14586069.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14 ):3683-8 [10919633.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):284-90 [16447821.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1090-5 [16226108.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):231-5 [12539177.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):477-81 [7531224.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):595-602 [11469692.001]
  • [Cites] Yale J Biol Med. 1987 Sep-Oct;60(5):421-35 [3424875.001]
  • [Cites] Neurosurgery. 1991 Jul;29(1):47-54 [1870687.001]
  • [Cites] Science. 1999 Jun 4;284(5420):1677-9 [10356399.001]
  • [Cites] Gut. 2003 Dec;52(12):1764-7 [14633958.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Ann Surg. 1995 Dec;222(6):695-9 [8526575.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):134-9 [17525623.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2004;1:683-6 [17271769.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] Microvasc Res. 1998 May;55(3):201-14 [9657920.001]
  • [Cites] J Endocrinol Invest. 2003 Jan;26(1):23-8 [12602530.001]
  • [Cites] Annu Rev Biomed Eng. 2004;6:427-52 [15255776.001]
  • [Cites] Nat Med. 1998 Sep;4(9):984 [9734370.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):454-66 [7509851.001]
  • [Cites] J Vasc Res. 2000 Jul-Aug;37(4):282-96 [10965227.001]
  • [Cites] J Anat. 2007 Nov;211(5):673-80 [17784937.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):115-124 [12114647.001]
  • [Cites] Microvasc Res. 2004 Mar;67(2):117-24 [15020202.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] J Theor Biol. 2001 Sep 21;212(2):183-90 [11531384.001]
  • [Cites] Microvasc Res. 1996 Jan;51(1):2-14 [8812748.001]
  • [Cites] J Pathol. 1997 May;182(1):1-8 [9227334.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1995 Dec;36(13):2749-55 [7499097.001]
  • [Cites] Folia Histochem Cytobiol. 1987;25(2):115-8 [2822497.001]
  • [Cites] Theor Biol Med Model. 2005 Jul 19;2:26 [16029490.001]
  • [Cites] Dermatology. 1999;198(2):212-7 [10325485.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3305-7 [11595729.001]
  • (PMID = 18327622.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 75
  •  go-up   go-down


2. Thomas JL, Bucholtz KM, Sun J, Mack VL, Kacsoh B: Structural basis for the selective inhibition of human 3beta-hydroxysteroid dehydrogenase 1 in human breast tumor MCF-7 cells. Mol Cell Endocrinol; 2009 Mar 25;301(1-2):174-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural basis for the selective inhibition of human 3beta-hydroxysteroid dehydrogenase 1 in human breast tumor MCF-7 cells.
  • Human 3beta-hydroxysteroid dehydrogenase/isomerase type 1 (3beta-HSD1) is a critical enzyme in the conversion of DHEA to estradiol in breast tumors and may be a target enzyme for inhibition in the treatment of breast cancer in postmenopausal women.
  • Human 3beta-HSD2 participates in the production of cortisol and aldosterone in the human adrenal gland in this population.
  • In our recombinant human breast tumor MCF-7 Tet-off cells that express either 3beta-HSD1 or 3beta-HSD2, trilostane and epostane inhibit the DHEA-induced proliferation of MCF-7 3beta-HSD1 cells with 12- to 16-fold lower IC(50) values compared to the MCF-7 3beta-HSD2 cells.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. ESTRONE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol Interact. 2001 Jan 30;130-132(1-3):637-50 [11306082.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Jul;111(1-2):66-73 [18524572.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16778-85 [14966133.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 7;1654(2):123-43 [15172700.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Med Chem. 1984 Jul;27(7):928-31 [6330362.001]
  • [Cites] J Steroid Biochem. 1989 Aug;33(2):209-17 [2770297.001]
  • [Cites] J Steroid Biochem. 1990 Jun;36(1-2):117-23 [2362440.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):421-35 [1562516.001]
  • [Cites] Biochemistry. 1996 Feb 27;35(8):2557-66 [8611559.001]
  • [Cites] J Endocrinol. 1996 Sep;150 Suppl:S189-207 [8943802.001]
  • [Cites] J Bone Miner Res. 1997 Mar;12(3):464-71 [9076590.001]
  • [Cites] Endocr Rev. 1997 Oct;18(5):701-15 [9331549.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):267-71 [9365200.001]
  • [Cites] J Steroid Biochem Mol Biol. 1998 Sep;66(5-6):327-34 [9749838.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):66-81 [9892013.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):619-29 [15545664.001]
  • [Cites] Endocr Res. 2004 Nov;30(4):935-41 [15666848.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21321-8 [15797861.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 May;95(1-5):151-4 [15970439.001]
  • [Cites] Hum Reprod. 2006 Jan;21(1):309-17 [16253961.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Sep;101(1):50-60 [16889958.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):80-7 [17624763.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42795-801 [12205101.001]
  • (PMID = 18955108.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114717-21; United States / NCI NIH HHS / CA / R01 CA114717; United States / NCI NIH HHS / CA / CA114717; United States / NCI NIH HHS / CA / R01 CA114717-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Coenzymes; 0 / Enzyme Inhibitors; 0 / Mutant Proteins; 0 / RNA, Messenger; 08J2K08A3Y / Dihydrotestosterone; 2DI9HA706A / Estrone; 459AG36T1B / Dehydroepiandrosterone; 4TI98Z838E / Estradiol; 94ZLA3W45F / Arginine; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; L0FPV48Q5R / trilostane
  • [Other-IDs] NLM/ NIHMS101740; NLM/ PMC2667100
  •  go-up   go-down


3. Bennett PF, DeNicola DB, Bonney P, Glickman NW, Knapp DW: Canine anal sac adenocarcinomas: clinical presentation and response to therapy. J Vet Intern Med; 2002 Jan-Feb;16(1):100-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine anal sac adenocarcinomas: clinical presentation and response to therapy.
  • A retrospective study of 43 dogs with anal sac adenocarcinoma (ASAC) was performed to characterize the clinical presentation and response to treatment.
  • A variety of chemotherapeutic agents were administered, with partial remission (PR) recorded in 4 of 13 (31%) dogs treated with cisplatin and in 1 of 3 (33%) dogs treated with carboplatin.
  • We conclude that platinum chemotherapy has antitumor activity in canine apocrine gland carcinoma and that further study of these agents is warranted.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11822797.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 1CC1JFE158 / Dactinomycin; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Shan L, Yu M, Schut HA, Snyderwine EG: Susceptibility of rats to mammary gland carcinogenesis by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) varies with age and is associated with the induction of differential gene expression. Am J Pathol; 2004 Jul;165(1):191-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Susceptibility of rats to mammary gland carcinogenesis by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) varies with age and is associated with the induction of differential gene expression.
  • 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a heterocyclic amine found in cooked meat, induces mammary gland cancer when administered to adolescent female rats (43-day-old).
  • Genes showing altered expression specifically in 43-day-old rats included the Ras superfamily genes and genes associated with protein synthesis/degradation (lysosomal proteins, heat shock proteins, and proteasomes).
  • The microarray data support the notion that the mechanism of age-dependent susceptibility to mammary gland cancer is largely associated with differential responses in expression of genes involved in cellular differentiation, proliferation, and protein homeostasis.
  • [MeSH-major] Carcinogens / toxicity. Food. Gene Expression Regulation, Neoplastic / drug effects. Imidazoles / toxicity. Mammary Neoplasms, Experimental / chemically induced
  • [MeSH-minor] Aging. Animals. Cell Differentiation / drug effects. Cell Division / drug effects. Cluster Analysis. DNA Adducts / analysis. Disease Susceptibility. Female. Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1995 May 17;1262(1):64-8 [7772601.001]
  • [Cites] Int Rev Immunol. 1999;18(5-6):429-48 [10672495.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1352-4 [10944558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11391-6 [11005832.001]
  • [Cites] Carcinogenesis. 1995 Nov;16(11):2725-31 [7586192.001]
  • [Cites] J Cell Biol. 1996 Jul;134(1):25-35 [8698819.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):717-21 [8795573.001]
  • [Cites] Biochem Soc Symp. 1998;63:101-13 [9513715.001]
  • [Cites] Carcinogenesis. 1998 Jul;19(7):1209-15 [9683179.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1573-81 [9771927.001]
  • [Cites] Nutr Cancer. 1998;31(3):160-7 [9795967.001]
  • [Cites] Carcinogenesis. 1998 Dec;19(12):2181-5 [9886576.001]
  • [Cites] Carcinogenesis. 1999 Mar;20(3):353-68 [10190547.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7 Suppl):1765-1771s; discussion 1771s-1772s [10197594.001]
  • [Cites] J Cell Sci. 1999 May;112 ( Pt 10):1477-86 [10212142.001]
  • [Cites] Science. 1969 Aug 22;165(3895):810-1 [5796556.001]
  • [Cites] J Natl Cancer Inst. 1974 Feb;52(2):609-10 [4816015.001]
  • [Cites] Biochemistry. 1975 Jul;14(13):2895-903 [1148182.001]
  • [Cites] Br J Cancer. 1975 Feb;31(2):189-96 [809048.001]
  • [Cites] J Natl Cancer Inst. 1978 Jan;60(1):173-7 [415147.001]
  • [Cites] J Natl Cancer Inst. 1978 Dec;61(6):1439-49 [102856.001]
  • [Cites] J Natl Cancer Inst. 1978 Dec;61(6):1451-9 [102857.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Apr;5(2):165-85 [11149571.001]
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):204-23 [11169868.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):101-13 [11467446.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1993-2009 [11682629.001]
  • [Cites] Cell Growth Differ. 2001 Dec;12(12):649-56 [11751460.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:23-35 [11795441.001]
  • [Cites] Anal Biochem. 2002 Feb 15;301(2):314-24 [11814302.001]
  • [Cites] Eur J Biochem. 2002 Feb;269(4):1209-18 [11856354.001]
  • [Cites] Environ Mol Mutagen. 2002;39(2-3):165-70 [11921185.001]
  • [Cites] Mol Cell Biochem. 2002 Jan;229(1-2):35-44 [11936845.001]
  • [Cites] J Cell Mol Med. 2002 Jan-Mar;6(1):25-48 [12003667.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):877-84 [12016163.001]
  • [Cites] Surg Oncol. 2002 May;10(4):183-92 [12020673.001]
  • [Cites] Bioinformatics. 2002 May;18(5):774-5 [12050079.001]
  • [Cites] Proteomics. 2002 Jul;2(7):850-6 [12124930.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4540-4 [12183401.001]
  • [Cites] Environ Med. 1999 Dec;43(2):79-87 [12296368.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:145-52 [12351154.001]
  • [Cites] Cancer Lett. 2003 Jan 28;189(2):117-28 [12490304.001]
  • [Cites] Carcinogenesis. 2002 Dec;23(12):2123-8 [12507937.001]
  • [Cites] Endocr Relat Cancer. 2002 Dec;9(4):207-20 [12542399.001]
  • [Cites] Curr Med Chem. 2003 Mar;10(6):479-503 [12570694.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):179-92 [12612653.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):505-12 [12729585.001]
  • [Cites] Eur J Surg Oncol. 2003 Jun;29(5):475-9 [12798754.001]
  • [Cites] Metabolism. 2003 Jul;52(7):810-4 [12870152.001]
  • [Cites] J Endocrinol. 1966 Aug;35(4):331-40 [5923706.001]
  • [Cites] Am J Pathol. 1979 Sep;96(3):721-36 [112872.001]
  • [Cites] Cancer Res. 1980 Aug;40(8 Pt 1):2677-87 [7388818.001]
  • [Cites] J Natl Cancer Inst. 1981 Jul;67(1):155-61 [6788991.001]
  • [Cites] Carcinogenesis. 1981;2(12):1327-33 [6799218.001]
  • [Cites] J Natl Cancer Inst. 1983 Jan;70(1):209-12 [6571916.001]
  • [Cites] Int J Cancer. 1983 Mar 15;31(3):321-7 [6402455.001]
  • [Cites] Carcinogenesis. 1983;4(6):733-8 [6407772.001]
  • [Cites] Chem Biol Interact. 1985 Oct;55(1-2):13-21 [3933840.001]
  • [Cites] Lab Invest. 1990 Mar;62(3):244-78 [2107367.001]
  • [Cites] Mol Cell Biol. 1991 Aug;11(8):3842-9 [1712897.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1477-80 [1540955.001]
  • [Cites] Carcinogenesis. 1992 Sep;13(9):1535-9 [1394836.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 6;85(1):25-31 [8416252.001]
  • [Cites] Cancer Lett. 1992 Dec 24;67(2-3):117-24 [1483260.001]
  • [Cites] Epidemiol Rev. 1993;15(1):7-16 [8405214.001]
  • [Cites] Carcinogenesis. 1994 Nov;15(11):2429-33 [7955086.001]
  • (PMID = 15215175.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / DNA Adducts; 0 / Imidazoles; 909C6UN66T / 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  • [Other-IDs] NLM/ PMC1618529
  •  go-up   go-down


5. Alesci S, Perera SM, Lai EW, Kukura C, Abu-Asab M, Tsokos M, Morris JC, Pacak K: Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: potential clinical and therapeutic relevance. Endocrinology; 2007 Aug;148(8):3900-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection of MPC cells with the Ad.C2.TK vector sensitized them to the cytotoxic effect of the antiviral drug ganciclovir, in direct proportion to the fraction of cells infected with the virus.
  • [MeSH-major] Adenoviridae / genetics. Adrenal Gland Neoplasms / therapy. Chromaffin Cells / physiology. Genetic Therapy / methods. Genetic Vectors. Pheochromocytoma / therapy
  • [MeSH-minor] Animals. Antiviral Agents. Cattle. Cell Line, Tumor. Cell Survival. Ganciclovir. Herpesvirus 1, Human / genetics. Mice. Mice, Knockout. Microscopy, Electron. Norepinephrine / pharmacokinetics. Thymidine Kinase / genetics. Transgenes / genetics. Tritium

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Virol. 2001 Dec;65(4):710-8 [11745936.001]
  • [Cites] Neuropharmacology. 2006 Jul;51(1):18-26 [16616768.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7484-9 [12032309.001]
  • [Cites] Horm Metab Res. 2002 Jun;34(6):279-87 [12173067.001]
  • [Cites] Curr Gene Ther. 2002 Sep;2(3):307-22 [12189718.001]
  • [Cites] Clin Infect Dis. 2002 Oct 1;35(7):808-18 [12228817.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:177-92 [12381553.001]
  • [Cites] J Neurosci Methods. 2002 Dec 31;122(1):91-6 [12535768.001]
  • [Cites] JAMA. 1992 Mar 4;267(9):1244-52 [1538563.001]
  • [Cites] J Biol Chem. 1993 May 25;268(15):10983-9 [8496162.001]
  • [Cites] Anal Biochem. 1995 Apr 10;226(2):212-20 [7793620.001]
  • [Cites] Gene Ther. 1994 Nov;1(6):367-84 [7584103.001]
  • [Cites] Mutat Res. 1995 Dec;333(1-2):181-8 [8538626.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1831-5 [8700844.001]
  • [Cites] World J Surg. 1996 Sep;20(7):916-21; discussion 922 [8678971.001]
  • [Cites] Clin Infect Dis. 1998 Nov;27(5):1194-200 [9827268.001]
  • [Cites] Hypertens Res. 2003 Feb;26 Suppl:S71-8 [12630814.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):1-44 [14769826.001]
  • [Cites] Expert Opin Biol Ther. 2004 Aug;4(8):1225-39 [15268658.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):568-80 [15294882.001]
  • [Cites] Am J Pathol. 1974 May;75(2):363-74 [4362916.001]
  • [Cites] Am J Pathol. 1974 May;75(2):375-94 [4362917.001]
  • [Cites] Am J Vet Res. 1975 Aug;36(08):1095-8 [168796.001]
  • [Cites] Arkh Patol. 1978;40(5):32-6 [210738.001]
  • [Cites] Can J Comp Med. 1978 Oct;42(4):466-72 [217508.001]
  • [Cites] J Human Stress. 1979 Sep;5(3):18-28 [225383.001]
  • [Cites] Am J Med. 1980 May;68(5):725-32 [6246799.001]
  • [Cites] J Neurosci Methods. 1981 Oct;4(3):227-41 [7300429.001]
  • [Cites] J Auton Nerv Syst. 1983 Jan;7(1):59-86 [6188774.001]
  • [Cites] Mol Pharmacol. 1984 Nov;26(3):539-46 [6493209.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5276-81 [3019523.001]
  • [Cites] J Natl Cancer Inst. 1990 Feb 21;82(4):297-300 [2299679.001]
  • [Cites] Hum Gene Ther. 1999 Oct 10;10(15):2515-26 [10543616.001]
  • [Cites] Blood. 1999 Dec 15;94(12):3968-75 [10590040.001]
  • [Cites] Gene Ther. 1999 Nov;6(11):1898-903 [10602386.001]
  • [Cites] Hum Gene Ther. 1999 Dec 10;10(18):2973-85 [10609658.001]
  • [Cites] Science. 1999 Dec 17;286(5448):2244-5 [10636774.001]
  • [Cites] Mol Genet Metab. 2000 Apr;69(4):269-76 [10870844.001]
  • [Cites] Cell Tissue Res. 2000 Dec;302(3):309-20 [11151443.001]
  • [Cites] Endocr Res. 2000 Nov;26(4):833-42 [11196460.001]
  • [Cites] Lancet. 2001 Sep 1;358(9283):727-9 [11551583.001]
  • [Cites] J Pediatr Surg. 1999 Feb;34(2):235-41 [10052795.001]
  • [Cites] Gene Ther. 1999 Jan;6(1):57-62 [10341876.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 14;260(3):712-7 [10403831.001]
  • [Cites] Gene Ther. 1999 Jul;6(7):1249-57 [10455433.001]
  • [Cites] Eur J Cell Biol. 1999 Aug;78(8):525-32 [10494858.001]
  • [Cites] Trends Endocrinol Metab. 2005 Mar;16(2):66-72 [15734147.001]
  • [Cites] Expert Opin Biol Ther. 2005 May;5(5):639-62 [15934840.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):665-75 [16112304.001]
  • [Cites] J Neurosci. 2002 Apr 1;22(7):2427-33 [11923406.001]
  • (PMID = 17525127.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 10028-17-8 / Tritium; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir; X4W3ENH1CV / Norepinephrine
  • [Other-IDs] NLM/ NIHMS43415; NLM/ PMC2527237
  •  go-up   go-down


6. Arulkumaran S, Ramprasath VR, Shanthi P, Sachdanandam P: Restorative effect of Kalpaamruthaa, an indigenous preparation, on oxidative damage in mammary gland mitochondrial fraction in experimental mammary carcinoma. Mol Cell Biochem; 2006 Oct;291(1-2):77-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restorative effect of Kalpaamruthaa, an indigenous preparation, on oxidative damage in mammary gland mitochondrial fraction in experimental mammary carcinoma.
  • Recent studies have shown that Semecarpus anacardium Linn nut milk extract (SA), a promising antioxidant and anticancer drug, exerts its anticancer effect through reducing or quenching reactive oxygen species under different conditions.
  • A vehicle treated control and drug control groups were also included.
  • The mitochondrial fraction of untreated DMBA-induced mammary gland showed 2.61-fold increase in lipid peroxidation level and abnormal changes in the activities/levels of mitochondrial enzymic (superoxide dismutase, glutathione peroxidase and glutathione reductase) and non-enzymic (glutathione, vitamin C and vitamin E) antioxidants were observed.
  • [MeSH-major] Mammary Glands, Animal / pathology. Mammary Neoplasms, Experimental / drug therapy. Mitochondria / drug effects. Oxidative Stress / drug effects. Plant Extracts / pharmacology. Plant Extracts / therapeutic use. Semecarpus / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Antineoplastic Agents, Phytogenic / therapeutic use. Antioxidants / metabolism. Female. Lipid Peroxidation / drug effects. Phytotherapy. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Free Radic Biol Med. 2004 Aug 1;37(3):287-303 [15223063.001]
  • [Cites] Crit Rev Food Sci Nutr. 2004;44(4):253-73 [15462129.001]
  • [Cites] Pharmacol Res. 1997 Sep;36(3):187-92 [9367662.001]
  • [Cites] J Pharm Pharmacol. 2003 Sep;55(9):1283-90 [14604472.001]
  • [Cites] Am Pharm. 1994 Sep;NS34(9):26-35 [7977023.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1441-4 [14641084.001]
  • [Cites] Indian J Exp Biol. 1999 Jul;37(7):676-80 [10522157.001]
  • [Cites] Biochem J. 1952 Oct;52(2):185-96 [13018205.001]
  • [Cites] Science. 1973 Feb 9;179(4073):588-90 [4686466.001]
  • [Cites] Tumour Biol. 1988;9(5):241-8 [2973647.001]
  • [Cites] Indian J Exp Biol. 2000 Dec;38(12):1177-82 [11411037.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2061-7 [167945.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):106S-111S [11560984.001]
  • [Cites] J Biol Chem. 1948 Jul;174(3):961-77 [18871256.001]
  • [Cites] Prog Exp Tumor Res. 1978;22:190-274 [149996.001]
  • [Cites] J Photochem Photobiol B. 1990 Apr 15;5(2):133-50 [2111395.001]
  • [Cites] Diabetes. 1997 Sep;46 Suppl 2:S14-8 [9285493.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4177-86 [10628372.001]
  • [Cites] Methods Enzymol. 1984;105:138-47 [6727662.001]
  • [Cites] Eur J Biochem. 1974 Sep 16;47(3):469-74 [4215654.001]
  • [Cites] Pathol Biol (Paris). 1996 Jan;44(1):25-8 [8734296.001]
  • [Cites] Life Sci. 2004 Mar 12;74(17):2157-84 [14969719.001]
  • [Cites] Photochem Photobiol. 1988 Aug;48(2):195-9 [3222330.001]
  • [Cites] Anal Biochem. 1972 Jun;47(2):389-94 [4556490.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):838-49 [15019969.001]
  • [Cites] J Nat Prod. 2001 Dec;64(12 ):1527-32 [11754604.001]
  • [Cites] Pharmacol Rev. 2002 Mar;54(1):101-27 [11870261.001]
  • [Cites] Biochem J. 1997 May 15;324 ( Pt 1):1-18 [9164834.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Nutr. 2004 Jun;134(6):1459-66 [15173412.001]
  • [Cites] Biochem Biophys Res Commun. 1974 Feb 4;56(3):836-42 [4151195.001]
  • [Cites] Free Radic Biol Med. 2004 Mar 15;36(6):718-44 [14990352.001]
  • [Cites] Methods Enzymol. 1979;62:3-11 [440112.001]
  • [Cites] Biochim Biophys Acta. 1979 Jan 4;582(1):67-78 [760819.001]
  • [Cites] J Ethnopharmacol. 2001 May;75(2-3):65-9 [11297836.001]
  • [Cites] Braz J Med Biol Res. 2004 Jul;37(7):1029-34 [15264010.001]
  • (PMID = 16953336.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Plant Extracts
  •  go-up   go-down


7. Venclauskas L, Saladzinskas Z, Tamelis A, Pranys D, Pavalkis D: Mucinous adenocarcinoma arising in an anorectal fistula. Medicina (Kaunas); 2009;45(4):286-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous adenocarcinoma in association with chronic anal fistula is a rare case in clinical practice.
  • The aim of this article was to report a rare case of anal gland mucinous adenocarcinoma in a patient who was treated in the Hospital of Kaunas University of Medicine.
  • Endoanal ultrasound findings showed soft tissue induration at the site of anorectal fistula, no tumor in the rectum wall.
  • Histological examination after abdominoperineal resection revealed anal duct mucinous adenocarcinoma pT2 N0 L0 V0 R0, G2.
  • [MeSH-major] Adenocarcinoma, Mucinous. Anus Neoplasms. Rectal Fistula / complications
  • [MeSH-minor] Abscess / complications. Aged. Anal Canal / pathology. Humans. Male. Neoplasm Staging. Perineum

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19423959.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


8. Rabbani ZN, Spasojevic I, Zhang X, Moeller BJ, Haberle S, Vasquez-Vivar J, Dewhirst MW, Vujaskovic Z, Batinic-Haberle I: Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med; 2009 Oct 1;47(7):992-1004
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor.
  • The goal of this study was to prove if and why a catalytic SOD mimic/peroxynitrite scavenger would exert anti-cancer effects, i.e., to evaluate whether the attenuation of the oxidative stress by MnTE-2-PyP(5+) could suppress tumor growth in a 4T1 mouse breast tumor model.
  • Tumor cells were implanted into Balb/C mouse flanks.
  • Intratumoral hypoxia (pimonidazole, carbonic anhydrase), HIF-1alpha, VEGF, proliferating capillary index (CD105), microvessel density (CD31), protein nitration, DNA oxidation (8-OHdG), NADPH oxidase (Nox-4), apoptosis (CD31), macrophage infiltration (CD68), and tumor drug levels were assessed.
  • With 2 mg/kg/day a trend toward tumor growth delay was observed, and a significant trend was observed with 15 mg/kg/day.
  • The 7.5-fold increase in drug dose was accompanied by a similar (6-fold) increase in tumor drug levels.
  • The anti-cancer activity via HIF/VEGF pathways probably arises from the impact of the drug on the oxidative stress.
  • Mn porphyrins may be advantageous compared to other anti-cancer drugs, owing to their radioprotection of normal tissue and the ability to afford pain management in cancer patients via prevention of chronic morphine tolerance.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 2008 Sep 1;477(1):105-12 [18477465.001]
  • [Cites] Free Radic Biol Med. 2008 Oct 1;45(7):943-9 [18598757.001]
  • [Cites] Free Radic Biol Med. 2009 Jan 1;46(1):42-50 [18930813.001]
  • [Cites] Free Radic Biol Med. 2009 Jan 15;46(2):212-9 [18983908.001]
  • [Cites] Free Radic Res. 2009 Apr;43(4):329-39 [19259881.001]
  • [Cites] Free Radic Biol Med. 2009 Jul 1;47(1):72-8 [19361553.001]
  • [Cites] Free Radic Biol Med. 2007 May 15;42(10):1571-8 [17448904.001]
  • [Cites] Amino Acids. 2007;32(4):501-15 [17077966.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2007;53(1):3-14 [17519108.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):241-8 [17440683.001]
  • [Cites] Breast Cancer Res. 2007;9(3):209 [17601353.001]
  • [Cites] Nat Rev Drug Discov. 2007 Aug;6(8):662-80 [17667957.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):230-8 [17785204.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2373-80 [17893866.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5A):3101-9 [17970050.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Clin Biochem. 2000 Jun;33(4):279-84 [10936586.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25130-8 [10833514.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 1;30(11):1191-212 [11368918.001]
  • [Cites] FEBS Lett. 2001 Sep 14;505(2):269-74 [11566189.001]
  • [Cites] Breast Cancer Res. 2001;3(5):323-7 [11597322.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jun;282(6):C1212-24 [11997235.001]
  • [Cites] Arch Biochem Biophys. 2002 Jun 15;402(2):159-65 [12051659.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31963-71 [12070140.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):177-89 [12463738.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):6831-7 [12475974.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):845-55 [12678687.001]
  • [Cites] Kidney Int Suppl. 2003 May;(84):S22-4 [12694301.001]
  • [Cites] Protoplasma. 2003 May;221(1-2):117-27 [12768349.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Aug;285(2):C353-69 [12686516.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27432-8 [12700236.001]
  • [Cites] Free Radic Biol Med. 2004 Jan 15;36(2):233-47 [14744635.001]
  • [Cites] Free Radic Biol Med. 2004 Mar 15;36(6):718-44 [14990352.001]
  • [Cites] Novartis Found Symp. 2004;256:189-200; discussion 200-4, 259-69 [15027491.001]
  • [Cites] Cancer Cell. 2004 May;5(5):429-41 [15144951.001]
  • [Cites] Free Radic Biol Med. 2004 Aug 1;37(3):367-74 [15223070.001]
  • [Cites] Dalton Trans. 2004 Jun 7;(11):1696-702 [15252564.001]
  • [Cites] Diabetes. 2004 Oct;53(10):2559-68 [15448084.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Oct;18(5):973-90, vii [15474330.001]
  • [Cites] Free Radic Res. 2004 Oct;38(10):1119-32 [15512801.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Carcinogenesis. 1992 Jan;13(1):77-81 [1733575.001]
  • [Cites] Clin Exp Metastasis. 1995 Jan;13(1):16-22 [7820952.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] Biochem J. 1996 Jan 1;313 ( Pt 1):17-29 [8546679.001]
  • [Cites] J Biol Chem. 1998 Sep 18;273(38):24521-8 [9733746.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11715-20 [9751731.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1648-53 [9811314.001]
  • [Cites] Chem Res Toxicol. 1999 May;12(5):442-9 [10328755.001]
  • [Cites] Prostate. 2005 Feb 1;62(2):200-7 [15389790.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):77-89 [15543233.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1401-5 [15735027.001]
  • [Cites] Am J Pathol. 2005 Sep;167(3):627-35 [16127144.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):545-52 [16168847.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9190-3 [16230378.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8154-66 [16170370.001]
  • [Cites] Dalton Trans. 2006 Jan 28;(4):617-24 [16402149.001]
  • [Cites] Int J Hyperthermia. 2006 Jun;22(4):263-73 [16754348.001]
  • [Cites] Antioxid Redox Signal. 2006 Jul-Aug;8(7-8):1295-305 [16910777.001]
  • [Cites] J Leukoc Biol. 2006 Oct;80(4):705-13 [16864600.001]
  • [Cites] Adv Exp Med Biol. 2006;588:165-70 [17089888.001]
  • [Cites] Free Radic Res. 2007 Jan;41(1):8-14 [17164174.001]
  • [Cites] Neuropsychopharmacology. 2007 Feb;32(2):377-87 [16794574.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):573-80 [17236973.001]
  • [Cites] J Rheumatol. 2007 Feb;34(2):401-7 [17295437.001]
  • [Cites] Free Radic Biol Med. 2007 Apr 15;42(8):1193-200 [17382200.001]
  • [Cites] Med Res Rev. 2007 May;27(3):317-52 [16991100.001]
  • [Cites] Mol Cell. 2007 Apr 13;26(1):63-74 [17434127.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10260-7 [17974967.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10823-30 [18006827.001]
  • [Cites] Dalton Trans. 2008 Mar 7;(9):1233-42 [18283384.001]
  • [Cites] Free Radic Biol Med. 2008 Mar 15;44(6):982-9 [18082148.001]
  • [Cites] Free Radic Res. 2007 Nov;41(11):1273-82 [17957541.001]
  • [Cites] Neuroscience. 2008 Apr 22;153(1):120-30 [18353561.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):425-37 [18500244.001]
  • [Cites] Cancer Lett. 2008 Jul 8;265(2):239-49 [18353538.001]
  • [Cites] Free Radic Biol Med. 2008 Jul 15;45(2):201-10 [18457677.001]
  • (PMID = 19591920.001).
  • [ISSN] 1873-4596
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA014236-33; United States / NIAID NIH HHS / AI / U19 AI067798-04; United States / NCI NIH HHS / CA / CA098452-02; United States / NCI NIH HHS / CA / R01 CA098452-03; United States / NCI NIH HHS / CA / 5-P30-CA14236-33; United States / NCI NIH HHS / CA / R01 CA098452-04; United States / NIAID NIH HHS / AI / AI067798-04; United States / NIAID NIH HHS / AI / U19 AI067798; United States / NCI NIH HHS / CA / CA098452-04; United States / NIAID NIH HHS / AI / 5U19-AI-067798-04; United States / NCI NIH HHS / CA / R01 CA098452; United States / NCI NIH HHS / CA / P30 CA014236; United States / NIAID NIH HHS / AI / U19 AI067798-01; United States / NIAID NIH HHS / AI / U19AI67798-01; United States / NCI NIH HHS / CA / R01 CA098452-02; United States / NCI NIH HHS / CA / CA098452-03; United States / NCI NIH HHS / CA / P30 CA014236-33; United States / NCI NIH HHS / CA / R01 CA 098452
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Metalloporphyrins; 0 / manganese (III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin
  • [Other-IDs] NLM/ NIHMS136470; NLM/ PMC2749298
  •  go-up   go-down


9. Zhan X, Desiderio DM: Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics; 2010 Apr 28;3:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We obtained a series of pituitary adenoma proteomic expression data, including protein-mapping data (111 proteins), comparative proteomic data (56 differentially expressed proteins), and nitroproteomic data (17 nitroproteins).
  • There is a pressing need to clarify the significant signaling pathway networks that derive from those proteins in order to clarify and to better understand the molecular basis of pituitary adenoma pathogenesis and to discover biomarkers.
  • Statistical significant results were rationalized within the pituitary adenoma biological system with literature-based bioinformatics analyses.
  • The nitroproteomic data from a pituitary adenoma were related to cancer, cell death, lipid metabolism, and reproductive system disease, and the top canonical toxicity pathways mainly related to p38 MAPK signaling and cell-cycle G2/M transition regulation.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pineal Res. 2006 Apr;40(3):230-5 [16499559.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3177-87 [16540669.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):87-92 [16625855.001]
  • [Cites] Br Med Bull. 2005;75-76:81-97 [16684928.001]
  • [Cites] Anal Biochem. 2006 Jul 15;354(2):279-89 [16777052.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4630-2 [16892077.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4812-30 [16892093.001]
  • [Cites] Arch Biochem Biophys. 2006 Oct 1;454(1):7-15 [16962985.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9483-91 [17018604.001]
  • [Cites] Biochem J. 2007 Jan 1;401(1):1-11 [17150040.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):203-16 [17287410.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Mar;66(3):348-52 [17302867.001]
  • [Cites] Cancer. 1980 Aug 1;46(3):537-42 [6249483.001]
  • [Cites] Nature. 1987 Dec 10-16;330(6148):566-8 [2825031.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Apr;74(4):914-9 [1312542.001]
  • [Cites] Adv Cancer Res. 2004;92:95-118 [15530558.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 24;325(4):1180-6 [15555551.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):367-80 [15531919.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1524-9 [15611622.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):121-31 [17311537.001]
  • [Cites] Eur Respir J. 2007 Apr;29(4):643-50 [17182653.001]
  • [Cites] Drug News Perspect. 2007 Mar;20(2):109-17 [17440634.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3279-90 [17496922.001]
  • [Cites] Cardiovasc Res. 2007 Jul 15;75(2):261-74 [17498676.001]
  • [Cites] Med Hypotheses. 2007;69(4):826-8 [17368752.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Feb 1;226(3):236-43 [17980396.001]
  • [Cites] Antioxid Redox Signal. 2008 Mar;10(3):635-40 [17999628.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1211-6 [18230656.001]
  • [Cites] Pharmacol Res. 2008 May;57(5):325-31 [18455424.001]
  • [Cites] IUBMB Life. 2008 Jul;60(7):441-7 [18465793.001]
  • [Cites] Virology. 2008 Aug 1;377(2):319-29 [18570970.001]
  • [Cites] Pituitary. 2008;11(3):231-45 [18183490.001]
  • [Cites] Cell. 2008 Jul 11;134(1):112-23 [18614015.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):3540-8 [18714027.001]
  • [Cites] Neurochem Res. 2008 Dec;33(12):2502-9 [18998208.001]
  • [Cites] Mol Carcinog. 2009 Feb;48(2):91-104 [18618599.001]
  • [Cites] J Intern Med. 2009 Feb;265(2):193-209 [19192036.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11292-6 [7504302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):170-4 [7529411.001]
  • [Cites] No To Shinkei. 1994 Oct;46(10):948-54 [7826710.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):86-94 [7531951.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Dec;41(6):815-20 [7889619.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):376-81 [7493016.001]
  • [Cites] J Histochem Cytochem. 1997 Jun;45(6):847-57 [9199670.001]
  • [Cites] Neuroendocrinology. 1997 Dec;66(6):426-31 [9430448.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Jul;49(1):29-38 [9797844.001]
  • [Cites] Horm Res. 1999;51(5):242-7 [10559669.001]
  • [Cites] Front Neuroendocrinol. 2000 Jul;21(3):174-98 [10882539.001]
  • [Cites] Mol Endocrinol. 2000 Aug;14(8):1137-46 [10935539.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Sep;53(3):337-44 [10971451.001]
  • [Cites] Cell. 2000 Oct 13;103(2):239-52 [11057897.001]
  • [Cites] Z Rheumatol. 2000;59 Suppl 2:II/36-42 [11155802.001]
  • [Cites] Minerva Endocrinol. 2000 Sep-Dec;25(3-4):55-9 [11338396.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2631-7 [11397864.001]
  • [Cites] Med Hypotheses. 2001 Oct;57(4):429-31 [11601863.001]
  • [Cites] J Neurosci. 2001 Nov 1;21(21):8348-53 [11606622.001]
  • [Cites] Horm Res. 2001;55(5):229-35 [11740144.001]
  • [Cites] Arch Med Res. 2001 Nov-Dec;32(6):476-85 [11750723.001]
  • [Cites] Trends Pharmacol Sci. 2002 Jan;23(1):40-5 [11804650.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1048-55 [12170092.001]
  • [Cites] J Endocrinol. 2002 Sep;174(3):379-86 [12208657.001]
  • [Cites] Acta Neurol Scand. 2002 Dec;106(6):361-6 [12460142.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1911-2 [12471242.001]
  • [Cites] Curr Pharm Des. 2003;9(5):381-90 [12570815.001]
  • [Cites] Folia Histochem Cytobiol. 2003;41(2):87-90 [12722794.001]
  • [Cites] Proteomics. 2003 May;3(5):699-713 [12748949.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):561-5 [12891360.001]
  • [Cites] Mol Cell Endocrinol. 2003 Aug 29;206(1-2):49-62 [12943989.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):962-8 [14871826.001]
  • [Cites] Expert Rev Mol Med. 2002 Apr;4(9):1-19 [14987393.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2838-49 [15077147.001]
  • [Cites] Trends Mol Med. 2004 Mar;10(3):125-9 [15102355.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20096-107 [14985350.001]
  • [Cites] Front Horm Res. 2004;32:34-62 [15281339.001]
  • [Cites] Front Horm Res. 2004;32:110-26 [15281342.001]
  • [Cites] Acta Neurochir (Wien). 1980;51(3-4):195-201 [7368994.001]
  • [Cites] Free Radic Biol Med. 2005 May 15;38(10):1278-95 [15855047.001]
  • [Cites] Mass Spectrom Rev. 2005 Nov-Dec;24(6):783-813 [15495141.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10214-22 [16288009.001]
  • [Cites] Trends Mol Med. 2005 Dec;11(12):571-8 [16290020.001]
  • [Cites] Chem Res Toxicol. 2005 Dec;18(12):1779-91 [16359168.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 21;97(24):1800-1 [16368937.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • (PMID = 20426862.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR016679
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cell Cycle Proteins; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2884164
  •  go-up   go-down


10. Bauer JA, Frye G, Bahr A, Gieg J, Brofman P: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs. Invest New Drugs; 2010 Oct;28(5):694-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs.
  • PURPOSE: Given the limited options available to treat canine cancers, the use of companion animals for evaluating new drugs may identify better therapies for veterinary and human oncology.
  • The anti-tumor effects of nitrosylcobalamin (NO-Cbl), an apoptosis-inducing, vitamin B12-based carrier of nitric oxide (NO), was evaluated in four dogs with spontaneous cancer.
  • (1) A 13 year-old female spayed Giant Schnauzer with inoperable thyroid carcinoma and hypercalcemia. (2) A 6 year-old male neutered Golden Retriever with a malignant peripheral nerve sheath tumor (MPNST). (3) A ten yr-old neutered male Bichon Frise with apocrine gland anal sac adenocarcinoma (AGACA). (4) A 7 year-old female spayed Labrador mix with spinal meningioma following partial surgical resection.
  • Tumor regression was measured by physical exam and verified using ultrasound (case 1) and MRI (case 2-4).
  • (1) The Giant Schnauzer demonstrated a 77% reduction in tumor volume after ten weeks of daily NO-Cbl treatment. (2) The Golden Retriever demonstrated a 53% reduction in tumor volume after 15 months of daily NO-Cbl therapy. (3) The Bichon Frise demonstrated a 43% regression of the primary tumor and a 90% regression of an iliac lymph node measured by MRI after 15 months of treatment.
  • After 61 months, the dog currently has stable disease, normal liver enzymes, CBC analysis, and no evidence of toxicity. (4) The Labrador demonstrated complete regression of the residual tumor after 6 months of treatment.
  • The use of NO-Cbl capitalizes on the tumor-specific properties of the vitamin B12 receptor and represents a promising anti-cancer therapy.
  • [MeSH-major] Dog Diseases / drug therapy. Neoplasms / veterinary. Nitroso Compounds / therapeutic use. Vitamin B 12 / analogs & derivatives
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Dogs. Dose-Response Relationship, Drug. Female. Magnetic Resonance Imaging. Male. Tumor Burden. Ultrasonography

  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2011 Oct;29(5):1122
  • [Cites] Eur J Cancer. 2004 Apr;40(6):858-80 [15120042.001]
  • [Cites] J Vet Intern Med. 1988 Jan-Mar;2(1):41-6 [3221354.001]
  • [Cites] Nat Med. 2005 Oct;11(10):1018 [16211022.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):181-93 [15354401.001]
  • [Cites] J Am Vet Med Assoc. 1991 May 1;198(9):1618-21 [2061177.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Jan-Feb;34(1):19-25 [9527425.001]
  • [Cites] Vet Radiol Ultrasound. 2001 Sep-Oct;42(5):471-4 [11678572.001]
  • [Cites] J Small Anim Pract. 1999 May;40(5):206-10 [10385862.001]
  • [Cites] J Am Vet Med Assoc. 2006 Aug 15;229(4):542-8 [16910854.001]
  • [Cites] J Vet Intern Med. 2002 Jan-Feb;16(1):100-4 [11822797.001]
  • [Cites] Clin Tech Small Anim Pract. 2007 May;22(2):75-81 [17591293.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Jul;4(2):112-28 [16102268.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):239-44 [9625434.001]
  • [Cites] J Nucl Med. 1997 May;38(5):717-23 [9170435.001]
  • [Cites] Semin Vet Med Surg (Small Anim). 1996 Nov;11(4):225-34 [9020576.001]
  • [Cites] Aust Vet J. 2005 Jun;83(6):340-3 [15986909.001]
  • [Cites] Cancer Invest. 2000;18(8):781-92 [11107448.001]
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):568-80 [10852417.001]
  • [Cites] J Am Vet Med Assoc. 1975 Mar 1;166(5):511-7 [1112759.001]
  • [Cites] Aust Vet J. 2005 Apr;83(4):208-14 [15907038.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Mar-Apr;34(2):109-12 [9507422.001]
  • [Cites] Vet Pathol. 2004 Jul;41(4):307-18 [15232130.001]
  • [Cites] J Am Anim Hosp Assoc. 1997 Jul-Aug;33(4):307-12 [9204465.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):1010-9 [12096086.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39461-9 [12881518.001]
  • [Cites] J Am Vet Med Assoc. 1995 Apr 1;206(7):1007-9 [7768706.001]
  • [Cites] J Am Vet Med Assoc. 2003 Sep 15;223(6):825-31 [14507100.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] J Vet Intern Med. 1994 May-Jun;8(3):236-9 [8064663.001]
  • [Cites] J Am Anim Hosp Assoc. 1995 Jul-Aug;31(4):349-59 [7552669.001]
  • [Cites] In Vivo. 1994 Jan-Feb;8(1):133-43 [8054503.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(15):5588-94 [16847314.001]
  • [Cites] J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 [2599941.001]
  • [Cites] Vet Comp Oncol. 2003 Jun;1(2):94-104 [19379321.001]
  • [Cites] J Neurosurg Anesthesiol. 1994 Apr;6(2):111-5 [8012169.001]
  • [Cites] J Small Anim Pract. 1981 Mar;22(3):119-28 [7230749.001]
  • [Cites] Vet Surg. 2006 Apr;35(3):267-70 [16635006.001]
  • [Cites] Vet Pathol. 1998 May;35(3):223-6 [9598587.001]
  • [Cites] PLoS One. 2007 Dec 12;2(12):e1313 [18074035.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):97-105 [16761625.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):161-2 [16449674.001]
  • [Cites] J Am Vet Med Assoc. 1987 Sep 15;191(6):720-6 [3679964.001]
  • (PMID = 19557306.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095020
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitroso Compounds; 0 / nitrosylcobalamin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


11. de Noo ME, Tollenaar RA, Deelder AM, Bouwman LH: Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World J Gastroenterol; 2006 Nov 7;12(41):6594-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal adenocarcinoma (CRC) is the third most common type of cancer and the fourth most frequent cause of death due to cancer worldwide.
  • Given the natural history of CRC, early diagnosis appears to be the most appropriate tool to reduce disease-related mortality.
  • (1) proteins being abnormally produced or shed and added to the serum proteome, (2) proteins clipped or modified as a consequence of the disease process, or (3) proteins subtracted from the proteome owing to disease-related proteolytic degradation pathways.
  • This paper focuses on the current status of clinical proteomics research in oncology and in colorectal cancer especially, and will reflect on pitfalls and fears in this relatively new area of clinical medicine, which are reproducibility issues and pre-analytical factors, statistical issues, and identification and nature of discriminating proteins/peptides.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Proteomics / methods
  • [MeSH-minor] Biomarkers, Tumor / blood. Data Interpretation, Statistical. Humans. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2002 Dec;126(12):1518-26 [12456215.001]
  • [Cites] Proteomics. 2003 Jan;3(1):56-63 [12548634.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1045-53 [16574760.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1):24-34 [15726503.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):233-7 [12634797.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):489-90; author reply 490-1 [12644546.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):243-52 [12671663.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):267-75 [12671665.001]
  • [Cites] J Am Coll Surg. 2003 May;196(5):722-8 [12742204.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):433-40 [12882527.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1484-91 [12912828.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2904-11 [12912935.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Trends Biotechnol. 2002 Dec;20(12 Suppl):S30-4 [12570157.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):297-304 [12625789.001]
  • [Cites] Anal Chem. 2005 Nov 15;77(22):7232-41 [16285670.001]
  • [Cites] Clin Chem. 2005 Dec;51(12):2229-35 [16223889.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):26-30 [16395400.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] J Pathol. 2006 Apr;208(5):595-606 [16518808.001]
  • [Cites] Proteomics. 2006 Apr;6(7):2095-100 [16502467.001]
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1536-44 [16570345.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1068-76 [16603345.001]
  • [Cites] Biostatistics. 2003 Jul;4(3):449-63 [12925511.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] J Proteome Res. 2003 Jul-Aug;2(4):361-72 [12938926.001]
  • [Cites] Proteomics. 2003 Sep;3(9):1667-72 [12973722.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6105-9 [14559785.001]
  • [Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1560-70 [15018552.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):309-14 [15057290.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1448-53 [15131804.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2375-82 [15175439.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3127-31 [15457557.001]
  • [Cites] Ann Intern Med. 1997 May 15;126(10):811-22 [9148658.001]
  • [Cites] Eur J Cancer. 2004 Nov;40(17):2613-22 [15541962.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):16-22 [15598930.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):378-91 [15637400.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):963-5 [15709159.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):291-2 [15765078.001]
  • [Cites] BMC Bioinformatics. 2005;6:68 [15788095.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Feb;3(4):322-31 [15814023.001]
  • [Cites] Clin Sci (Lond). 2005 May;108(5):369-83 [15831087.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1685-95 [15887159.001]
  • [Cites] Clin Chem. 2005 Jun;51(6):973-80 [15845803.001]
  • [Cites] Am J Gastroenterol. 2005 Jun;100(6):1393-403 [15929776.001]
  • [Cites] Rapid Commun Mass Spectrom. 2005;19(12):1624-36 [15915451.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):972-81 [15952745.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]
  • [Cites] Dig Surg. 2005;22(4):276-81 [16174984.001]
  • [Cites] Adv Exp Med Biol. 2000;477:349-78 [10849763.001]
  • [Cites] J Pathol. 2000 Nov;192(3):280-8 [11054709.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jan;12(1):53-63 [11916161.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):132-41 [12118972.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):170; author reply 170-1 [12126845.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • (PMID = 17075970.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 69
  • [Other-IDs] NLM/ PMC4125662
  •  go-up   go-down


12. Sameni M, Cavallo-Medved D, Dosescu J, Jedeszko C, Moin K, Mullins SR, Olive MB, Rudy D, Sloane BF: Imaging and quantifying the dynamics of tumor-associated proteolysis. Clin Exp Metastasis; 2009;26(4):299-309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging and quantifying the dynamics of tumor-associated proteolysis.
  • Proteases from tumor-associated cells (e.g., fibroblasts, inflammatory cells, endothelial cells) as well as from tumor cells make important contributions to 'tumor proteolysis'.
  • Therefore, the recent development of techniques and reagents for live cell imaging of protease activity, in conjunction with informed knowledge of critical natural substrates, should help to define protease functions.
  • Here we describe live cell assays for imaging proteolysis, protocols for quantifying proteolysis and the use of such assays to follow the dynamics of proteolysis by tumor cells alone and tumor cells interacting with other cells found in the tumor microenvironment.
  • In addition, we describe an in vitro model that recapitulates the architecture of the mammary gland, a model designed to determine the effects of dynamic interactions with the surrounding microenvironment on 'tumor proteolysis' and the respective contributions of various cell types to 'tumor proteolysis'.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2003;5(3):130-5 [12793893.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2006;46:301-15 [16402907.001]
  • [Cites] Nat Chem Biol. 2005 Sep;1(4):203-9 [16408036.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):608-22 [16442099.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):716-28 [16469948.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5242-50 [16707449.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):231-47 [16807803.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11238-46 [17114237.001]
  • [Cites] Curr Opin Chem Biol. 2007 Feb;11(1):36-45 [17194619.001]
  • [Cites] Curr Pharm Des. 2007;13(3):253-61 [17313359.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2086-95 [17290405.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Mar;12(1):83-97 [17286208.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2850-8 [17547438.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):893-904 [17618273.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):800-8 [17851543.001]
  • [Cites] Nat Methods. 2007 Oct;4(10):822-7 [17901872.001]
  • [Cites] Rev Endocr Metab Disord. 2007 Sep;8(3):279-87 [17447144.001]
  • [Cites] Birth Defects Res C Embryo Today. 2007 Dec;81(4):270-85 [18228260.001]
  • [Cites] Neoplasia. 2008 Apr;10(4):314-29 [18392133.001]
  • [Cites] J Clin Neurosci. 2008 Jul;15(7):725-37 [18468901.001]
  • [Cites] Biol Chem. 2008 Aug;389(8):1117-21 [18710343.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1185-6 [10904098.001]
  • [Cites] Exp Cell Res. 2000 Nov 1;260(2):292-303 [11035924.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):496-504 [11228542.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):169-84 [11237532.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6642-50 [11426650.001]
  • [Cites] Biol Chem. 2001 May;382(5):785-8 [11517931.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Science. 2002 May 10;296(5570):1046-9 [12004111.001]
  • [Cites] Breast Cancer Res. 2003;5(3):140-6 [12793895.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Hum Cell. 2003 Mar;16(1):1-14 [12971620.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33 [14508090.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(6):956-63 [12955390.001]
  • [Cites] Mol Imaging. 2003 Jul;2(3):159-75 [14649059.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):379-91 [14973383.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):13-22 [14984764.001]
  • [Cites] Histochem Cell Biol. 2004 Apr;121(4):299-310 [15042374.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Front Biol. 1975;43(4):193-249 [780142.001]
  • [Cites] Lab Invest. 1978 Dec;39(6):531-40 [216851.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Carcinog. 1991;4(1):25-35 [2009132.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Breast Cancer Res. 2004;6(2):93-101 [14979914.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1163-76 [15841211.001]
  • [Cites] J Cell Biol. 2005 Jun 20;169(6):977-85 [15967816.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Jun;5(4):285-98 [15975049.001]
  • [Cites] Semin Cancer Biol. 2005 Oct;15(5):342-52 [15963732.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6870-6 [16007139.001]
  • [Cites] Circ Res. 2005 Nov 25;97(11):1093-107 [16306453.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cell. 2002 Oct 4;111(1):29-40 [12372298.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Expert Opin Ther Targets. 2003 Feb;7(1):71-88 [12556204.001]
  • [Cites] Breast Cancer Res. 2003;5(1):31-6 [12559043.001]
  • [Cites] Breast Cancer Res. 2003;5(2):101-6 [12631389.001]
  • [Cites] J Histochem Cytochem. 2003 Jun;51(6):821-9 [12754293.001]
  • [Cites] Cancer Cell. 2003 May;3(5):445-8 [12781362.001]
  • (PMID = 19082919.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA056586-17; United States / NCI NIH HHS / CA / R01 CA131990; United States / NCI NIH HHS / CA / R01 CA056586; United States / NCI NIH HHS / CA / CA 56586; United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / P30 CA 22453; United States / NCRR NIH HHS / RR / U54 RR 020843; United States / NIEHS NIH HHS / ES / P30 ES 06639; United States / NCI NIH HHS / CA / CA056586-17; United States / NCRR NIH HHS / RR / U54 RR020843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.- / Peptide Hydrolases
  • [Number-of-references] 70
  • [Other-IDs] NLM/ NIHMS223032; NLM/ PMC2991638
  •  go-up   go-down


13. Moreira JM, Cabezón T, Gromova I, Gromov P, Timmermans-Wielenga V, Machado I, Llombart-Bosch A, Kroman N, Rank F, Celis JE: Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy. Mol Oncol; 2010 Dec;4(6):539-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.
  • Our limited understanding of the biological impact of the whole spectrum of early breast lesions together with a lack of accurate molecular-based risk criteria for the diagnosis and assignment of prognostic significance to biopsy findings presents an important problem in the clinical management of patients harboring precancerous breast lesions.
  • As a result, there is a need to identify biomarkers that can better determine the outcome of early breast lesions by identifying subpopulations of cells in breast premalignant disease that are at high-risk of progression to invasive disease.
  • We review and present new data on the putative cell-progenitor marker cytokeratin 15 (CK15), and describe a novel marker, dihydropyriminidase-related protein 3 (DRP3) that in combination with CK15 and other well known proteins were used to define molecular phenotypes of normal human breast epithelial cells and their progenitors in resting acini, lactating alveoli, and large collecting ducts of the nipple.
  • At least two bona fide biomarkers of undifferentiated ERα/PgR negative luminal cells emerged from these studies, CK15 and c-KIT, which in combination with transformation markers may lead to the establishment of a protein signature able to identify breast precancerous at risk of progressing to invasive disease.
  • [MeSH-major] Biomarkers / metabolism. Breast Neoplasms. Epithelial Cells / metabolism. Mammary Glands, Human. Phenotype. Proteomics / methods
  • [MeSH-minor] Databases, Protein. Electrophoresis, Gel, Two-Dimensional / methods. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratin-15 / metabolism. Keratin-19 / metabolism. Mass Spectrometry / methods. Muscle Proteins / metabolism. Protein Array Analysis / methods. Protein Isoforms / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
  • [Cites] Genes Dev. 2009 Nov 15;23 (22):2563-77 [19933147.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jun;133(6):852-4 [19492876.001]
  • [Cites] Int J Cancer. 1985 Sep 15;36(3):299-306 [2411673.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1195-203 [16106024.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2009 Sep;45(8):442-50 [19533258.001]
  • [Cites] Pathology. 2009 Jan;41(1):36-9 [19089738.001]
  • [Cites] Mol Oncol. 2010 Oct;4(5):369-72 [20692213.001]
  • [Cites] Histopathology. 2008 Jan;52(1):11-9 [18171413.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(1):17-29 [19082706.001]
  • [Cites] J Pathol. 2009 Sep;219(1):131-40 [19562735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 May 4;107(18):8352-6 [20404174.001]
  • [Cites] Expert Rev Mol Diagn. 2010 May;10 (4):417-34 [20465497.001]
  • [Cites] Mol Diagn Ther. 2009 Dec 1;13(6):349-57 [19925032.001]
  • [Cites] J Pathol. 2006 Jul;209(3):307-16 [16604511.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):737-46 [12065684.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):402-4 [8542598.001]
  • [Cites] Breast Cancer Res. 2004;6(6):229-39 [15535852.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1337-44 [15042665.001]
  • [Cites] J Neurochem. 2005 Oct;95(2):466-74 [16135096.001]
  • [Cites] Mol Oncol. 2008 Dec;2(4):368-79 [19383358.001]
  • [Cites] J Surg Oncol. 1984 Jan;25(1):38-41 [6694391.001]
  • [Cites] Breast Cancer Res Treat. 1984;4(2):117-28 [6743838.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] Mol Oncol. 2010 Aug;4(4):357-68 [20663721.001]
  • [Cites] Acta Oncol. 1988;27(1):1-19 [3284552.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] Climacteric. 2007 Oct;10 Suppl 2:47-53 [17882673.001]
  • [Cites] Nat Rev Drug Discov. 2010 Oct;9(10):767-74 [20811384.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] BMB Rep. 2010 Jun;43(6):383-8 [20587327.001]
  • [Cites] Mol Oncol. 2010 Jun;4(3):209-29 [20537966.001]
  • [Cites] J Neurosci. 2003 Apr 1;23(7):2815-23 [12684468.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):1023-34 [18024329.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Breast Cancer. 2002;9(3):254-6 [12185338.001]
  • [Cites] J Neurobiol. 1999 Oct;41(1):158-64 [10504203.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):261-72 [16807805.001]
  • [Cites] Mol Oncol. 2010 Oct;4(5):385-96 [20688584.001]
  • [Cites] Tissue Eng Part B Rev. 2010 Jun;16(3):351-9 [20092396.001]
  • [Cites] Mol Oncol. 2008 Aug;2(2):115-52 [19383333.001]
  • [Cites] Oncogene. 2010 Aug 12;29(32):4555-66 [20543870.001]
  • [Cites] J Clin Pathol. 2000 Oct;53(10):778-83 [11064673.001]
  • [Cites] Gene. 1996 Nov 21;180(1-2):157-63 [8973361.001]
  • [Cites] FEBS Lett. 2006 May 22;580(12):2935-44 [16631754.001]
  • [Cites] Mol Endocrinol. 2011 Feb;25(2):199-211 [20861225.001]
  • [Cites] Mol Oncol. 2010 Dec;4(6):496-510 [20934395.001]
  • [Cites] Breast J. 2005 Sep-Oct;11(5):326-32 [16174153.001]
  • [Cites] Pathology. 2009 Jan;41(1):18-27 [19089736.001]
  • [Cites] J Clin Pathol. 1996 Jan;49(1):48-52 [8666685.001]
  • [Cites] Breast Dis. 2008;29:57-67 [19029625.001]
  • [Cites] Mol Oncol. 2010 Feb;4(1):65-89 [20005186.001]
  • [Cites] Histopathology. 2010 Aug;57(2):171-92 [20500230.001]
  • [Cites] Int J Cancer. 1996 Oct 21;69(5):408-14 [8900376.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):713-7 [1385336.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):344-9 [16400324.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12195-201 [9115293.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):24-32 [19383364.001]
  • [Cites] Mol Oncol. 2010 Dec;4(6):539-61 [21036680.001]
  • [Cites] Mol Oncol. 2010 Feb;4(1):19-37 [19913465.001]
  • [Cites] FEBS Lett. 2002 Dec 18;532(3):445-9 [12482610.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):417-26 [17325484.001]
  • [Cites] Maturitas. 2004 Sep 24;49(1):2-15 [15351091.001]
  • [Cites] Ann Oncol. 2008 May;19(5):1009-18 [18296422.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2317-27 [15160334.001]
  • [Cites] Hum Pathol. 2010 Jun;41(6):895-901 [20233620.001]
  • [Cites] Breast Cancer Res. 2005;7(5):190-7 [16168137.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 26;309(3):558-66 [12963026.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17 ):1784-92 [16251534.001]
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):369-77 [12832461.001]
  • [Cites] Histochem Cell Biol. 2008 Jun;129(6):705-33 [18461349.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):593-5 [17164227.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1307-12 [17182657.001]
  • [Cites] Cell Stem Cell. 2010 Sep 3;7(3):403-17 [20804975.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2716-25 [15837986.001]
  • [Cites] Mol Cell Proteomics. 2010 Nov;9(11):2529-44 [20739354.001]
  • [Cites] Braz J Med Biol Res. 1996 Sep;29(9):1105-8 [9181052.001]
  • [Cites] Breast Cancer Res. 2002;4(6):224-30 [12473168.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Mol Oncol. 2010 Dec;4(6):461-81 [20974554.001]
  • [Cites] Mod Pathol. 2010 May;23 Suppl 2:S1-7 [20436497.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):97-119 [19383289.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(2):93-109 [11519870.001]
  • [Cites] Eur J Gynaecol Oncol. 2009;30(6):635-9 [20099493.001]
  • [Cites] Mol Neurobiol. 2003 Aug;28(1):51-64 [14514985.001]
  • [Cites] Clin Chem Lab Med. 2009;47(6):666-84 [19445650.001]
  • [Cites] Int J Cancer. 2010 Dec 15;127(12):2893-917 [21351269.001]
  • [Cites] Mol Oncol. 2009 Jun;3(3):220-37 [19393583.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1051-61 [15254552.001]
  • [Cites] Arch Pathol Lab Med. 2010 Jul;134(7):e48-72 [20586616.001]
  • [Cites] Nat Rev Cancer. 2010 Sep;10(9):605-17 [20720569.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Breast Cancer Res. 2003;5(5):263-8 [12927037.001]
  • [Cites] Electrophoresis. 1997 Dec;18(15):2832-41 [9504817.001]
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):190-203 [11169867.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Breast Cancer Res. 2003;5(5):254-7 [12927035.001]
  • [Cites] Mol Oncol. 2008 Aug;2(2):153-60 [19383334.001]
  • [Cites] Pathol Res Pract. 2007;203(11):765-9 [17931792.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1997 Jan;2(1):19-27 [10887516.001]
  • [Cites] Adv Anat Pathol. 2005 Sep;12(5):256-64 [16210921.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Oncogene. 2000 Aug 17;19(35):3978-87 [10962554.001]
  • [Cites] Mol Oncol. 2009 Feb;3(1):33-44 [19383365.001]
  • [Cites] Mol Oncol. 2010 Dec;4(6):511-28 [20851695.001]
  • [Cites] Breast Cancer Res. 2004;6(1):1-11 [14680479.001]
  • [Cites] Breast Cancer Res. 2005;7(3):131-42 [15987443.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Mod Pathol. 2010 May;23 Suppl 2:S8-13 [20436505.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):327-44 [14754989.001]
  • [Cites] Science. 2010 Jul 30;329(5991):568-71 [20671189.001]
  • [Cites] BMC Cancer. 2006 Apr 07;6:86 [16603054.001]
  • [Cites] Brain Res. 2006 Nov 13;1119(1):40-9 [16987501.001]
  • [Cites] Adv Cancer Res. 1997;71:241-319 [9111868.001]
  • [Cites] BMC Cancer. 2010 Aug 19;10 :444 [20723242.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):531-42 [11706048.001]
  • [Cites] Mol Oncol. 2007 Jun;1(1):84-96 [18516279.001]
  • (PMID = 21036680.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DPYSL3 protein, human; 0 / Keratin-15; 0 / Keratin-19; 0 / Muscle Proteins; 0 / Protein Isoforms
  •  go-up   go-down


14. Bartusik D, Tomanek B, Siluk D, Kaliszan R, Fallone G: The application of 19F magnetic resonance ex vivo imaging of three-dimensional cultured breast cancer cells to study the effect of delta-tocopherol. Anal Biochem; 2009 Apr 15;387(2):315-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human gland mammary adenocarcinoma (MCF-7) and human T-lymphoblastoid (CEM) cells were cultured in the presence of delta-tocopherol at various concentrations (0-750 microM) for 5 days.
  • [MeSH-major] Breast Neoplasms / pathology. Magnetic Resonance Imaging / methods. Tocopherols / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Female. Fluorine. Humans. Oxygen / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. FLUORINE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454246.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-66-2 / Tocopherols; 284SYP0193 / Fluorine; JU84X1II0N / delta-tocopherol; S88TT14065 / Oxygen
  •  go-up   go-down


15. Betancourt AM, Eltoum IA, Desmond RA, Russo J, Lamartiniere CA: In utero exposure to bisphenol A shifts the window of susceptibility for mammary carcinogenesis in the rat. Environ Health Perspect; 2010 Nov;118(11):1614-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Our goal in this study was to determine whether prenatal exposure to BPA predisposes the adult rat mammary gland to carcinogenesis.
  • RESULTS: Prenatal exposure of the dam to 250 microg BPA/kg BW combined with a single exposure of female offspring to DMBA on PND100, but not on PND50, significantly increased tumor incidence while decreasing tumor latency compared with the control group.
  • Differentially regulated proteins in the mammary gland included estrogen receptor-alpha, progesterone receptor-A, Bcl-2, steroid receptor coactivators, epidermal growth factor receptor, phospho-insulinlike growth factor 1 receptor, and phospho-Raf.
  • CONCLUSIONS: Our study demonstrates that oral prenatal exposure to BPA increases mammary cancer susceptibility in offspring and shifts the window of susceptibility for DMBA-induced tumorigenesis in the rat mammary gland from PND50 to PND100.
  • These changes are accompanied by differential effects of prenatal BPA exposure on the expression of key proteins involved in cell proliferation.

  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BISPHENOL A DISODIUM SALT .
  • Hazardous Substances Data Bank. BISPHENOL A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Appl Pharmacol. 2000 Nov 1;168(3):225-34 [11042095.001]
  • [Cites] Genome Res. 2010 Jun;20(6):733-44 [20442245.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):903-7 [11221879.001]
  • [Cites] Biol Reprod. 2001 Oct;65(4):1215-23 [11566746.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):67-76 [12160087.001]
  • [Cites] Environ Health Perspect. 2002 Nov;110(11):A703-7 [12417499.001]
  • [Cites] J Pharm Biomed Anal. 2003 Jan 15;30(6):1743-9 [12485715.001]
  • [Cites] Cancer Res. 1972 Jul;32(7):1404-15 [4337828.001]
  • [Cites] J Natl Cancer Inst. 1975 Apr;54(4):1007-9 [805252.001]
  • [Cites] Cancer Res. 1976 Feb;36(2 Pt 1):319-24 [816459.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Sep;74(9):4020-4 [410031.001]
  • [Cites] J Natl Cancer Inst. 1978 Dec;61(6):1451-9 [102857.001]
  • [Cites] Am J Pathol. 1979 Sep;96(3):721-36 [112872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jul;79(13):3987-91 [6955785.001]
  • [Cites] Environ Health Perspect. 1983 Mar;49:185-99 [6403347.001]
  • [Cites] Cancer Res. 1985 Aug;45(8):3415-43 [3926298.001]
  • [Cites] Monogr Endocrinol. 1989;32:1-133 [2695836.001]
  • [Cites] Lab Invest. 1990 Mar;62(3):244-78 [2107367.001]
  • [Cites] J Cell Biol. 1994 Nov;127(4):1097-109 [7962070.001]
  • [Cites] Environ Health Perspect. 1995 Jun;103(6):608-12 [7556016.001]
  • [Cites] Environ Health Perspect. 1996 Mar;104(3):298-305 [8919768.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1623-9 [9771934.001]
  • [Cites] Br J Cancer. 1965 Mar;19:160-6 [14289051.001]
  • [Cites] Environ Health Perspect. 2005 Apr;113(4):391-5 [15811827.001]
  • [Cites] Arch Toxicol. 2005 May;79(5):243-52 [15902421.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1067-78 [15920556.001]
  • [Cites] J Nutr. 2005 Dec;135(12 Suppl):2953S-2959S [16317154.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S56-69 [16690810.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5624-32 [16740699.001]
  • [Cites] Toxicology. 2006 Sep 21;226(2-3):79-89 [16860916.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13(4):1135-45 [17158759.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1405-11 [17332282.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):80-6 [17366824.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):116-21 [17366830.001]
  • [Cites] Reprod Toxicol. 2007 Apr-May;23(3):383-90 [17123778.001]
  • [Cites] J Endocrinol. 2008 Jan;196(1):101-12 [18180321.001]
  • [Cites] Acta Oncol. 2009;48(4):522-31 [19173092.001]
  • [Cites] Environ Health Perspect. 2009 Jun;117(6):910-5 [19590682.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8217-22 [19843848.001]
  • [Cites] J Proteomics. 2010 Apr 18;73(6):1241-53 [20219716.001]
  • [CommentIn] Environ Health Perspect. 2010 Nov;118(11):A490 [21465746.001]
  • (PMID = 20675265.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / U01 ES012771; United States / NIEHS NIH HHS / ES / U01 ES/CA ES012771
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Carcinogens, Environmental; 0 / Endocrine Disruptors; 0 / Phenols; MLT3645I99 / bisphenol A
  •  go-up   go-down


16. Shen Q, Brown PH: Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia; 2003 Jan;8(1):45-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.
  • Transformation of breast cells occurs through loss or mutation of tumor suppressor genes, or activation or amplification of oncogenes, leading to deregulation of signal transduction pathways, abnormal amplification of growth signals, and aberrant expression of genes that ultimately transform the cells into invasive cancer.
  • Multiple alterations in signal pathways and transcription factors are observed in mammary gland tumorigenesis.
  • Therefore, proteins in pathways that are altered during the process of mammary tumorigenesis may be promising targets of future chemopreventive drugs.
  • Many newly-developed synthetic or natural compounds/agents are now under testing in preclinical studies and clinical trials.
  • Receptor selective retinoids, receptor tyrosine kinase inhibitors (TKIs), SERMs, Cox-2 inhibitors, and others are some of the promising novel agents for the prevention of breast cancer.
  • The chemopreventive activity of these agents and other novel signal transduction inhibitors are discussed in this chapter.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Breast Neoplasms / prevention & control. Signal Transduction. Transcription Factors / metabolism
  • [MeSH-minor] Enzyme Inhibitors / pharmacology. Humans. Models, Biological. Protein-Tyrosine Kinases / antagonists & inhibitors. Receptors, Cytoplasmic and Nuclear / metabolism. Receptors, Estrogen / biosynthesis. Receptors, Estrogen / metabolism. Receptors, Retinoic Acid / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1997 Jan 15;11(2):179-86 [9009201.001]
  • [Cites] J Clin Invest. 2001 Jul;108(1):73-81 [11435459.001]
  • [Cites] Steroids. 2002 Aug;67(9):789-98 [12123791.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):475-82 [12478662.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1911-2 [12471242.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21272-9 [11287416.001]
  • [Cites] Lancet. 2002 Sep 14;360(9336):817-24 [12243915.001]
  • [Cites] J Steroid Biochem. 1986 Jan;24(1):373-6 [3754600.001]
  • [Cites] Oncogene. 2001 May 17;20(22):2771-80 [11420689.001]
  • [Cites] Int J Oncol. 2002 Jun;20(6):1109-22 [12011987.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1159-66 [11850835.001]
  • [Cites] Cancer Res. 1982 Mar;42(3):1116-9 [6277475.001]
  • [Cites] Biochemistry. 1998 Jun 23;37(25):8879-85 [9636029.001]
  • [Cites] Histochem J. 2002 Jan-Feb;34(1-2):35-40 [12365798.001]
  • [Cites] Carcinogenesis. 1999 Jul;20(7):1201-8 [10383890.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):431-7 [11485901.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17397-405 [11859072.001]
  • [Cites] Mol Biol Cell. 2001 May;12 (5):1445-55 [11359934.001]
  • [Cites] Cancer Lett. 1998 Jan 9;122(1-2):165-75 [9464506.001]
  • [Cites] Cancer Invest. 2002;20 Suppl 2:30-7 [12442347.001]
  • [Cites] J Neurochem. 2002 Sep;82(6):1424-34 [12354290.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2530-5 [12171880.001]
  • [Cites] Anticancer Drugs. 2002 Sep;13(8):891-7 [12394276.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):883-8 [12213582.001]
  • [Cites] Breast Cancer Res Treat. 2001 Nov;70(1):11-20 [11767000.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):479-84 [9458093.001]
  • [Cites] Annu Rev Immunol. 2000;18:621-63 [10837071.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6550-65 [11426640.001]
  • [Cites] Lancet. 1998 Jul 11;352(9122):93-7 [9672273.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74 [12010861.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] Science. 1988 May 13;240(4854):889-95 [3283939.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36803-10 [10969078.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1494-503 [12359858.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2835-42 [12231524.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4781-90 [12183438.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7507-17 [11606387.001]
  • [Cites] Bioorg Med Chem. 2002 Nov;10(11):3481-7 [12213462.001]
  • [Cites] Oncogene. 2002 Sep 19;21(42):6510-9 [12226754.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1214-20 [11350886.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1083-6 [11861386.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):389-97 [10454214.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4 Suppl 13):33-45 [12170431.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):219-25 [11566613.001]
  • [Cites] Mol Pharmacol. 1988 Jun;33(6):650-6 [3132609.001]
  • [Cites] Bioorg Med Chem Lett. 2003 Jan 20;13(2):277-80 [12482439.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Sep;34(9):1051-8 [12009300.001]
  • [Cites] Physiol Rev. 2001 Oct;81(4):1535-65 [11581496.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2424-8 [11289109.001]
  • [Cites] Biochem J. 2002 Sep 1;366(Pt 2):673-80 [12069688.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7680-9 [12400010.001]
  • [Cites] Jpn J Cancer Res. 2002 Jan;93(1):32-5 [11802805.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2820-7 [12231522.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):479-86 [10617642.001]
  • [Cites] J Neurosci. 1998 Jan 1;18(1):104-11 [9412490.001]
  • [Cites] Biochemistry. 1998 Jun 30;37(26):9579-85 [9649341.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14 ):3838-47 [10919658.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4472-6 [2525951.001]
  • [Cites] Cell Growth Differ. 1991 Oct;2(10):475-82 [1751404.001]
  • [Cites] Cell Growth Differ. 2000 Feb;11(2):99-110 [10714766.001]
  • [Cites] Braz J Med Biol Res. 2002 Jan;35(1):1-9 [11743608.001]
  • [Cites] Exp Cell Biol. 1987;55(3):136-44 [3666278.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):790-5 [9053506.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] EMBO J. 2000 Mar 15;19(6):1301-11 [10716930.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 4):87-94 [11894018.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):32008-15 [11410599.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1274-80 [9032254.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2456-71 [11331325.001]
  • [Cites] Endocr Relat Cancer. 2001 Jun;8(2):97-114 [11397667.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Apr;45(4):257-63 [8388708.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3605-11 [10910075.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):122-8 [11782368.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11(4):319-25 [12195157.001]
  • [Cites] Cell Growth Differ. 2000 Dec;11(12):655-64 [11149601.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4308-13 [10485477.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):471-5 [9816192.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12 ):3824-31 [12473596.001]
  • [Cites] Infect Immun. 1999 Aug;67(8):3824-9 [10417144.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1997 Oct;2(4):365-72 [10935024.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jul;302(1):138-44 [12065710.001]
  • [Cites] Curr Opin Investig Drugs. 2000 Nov;1(3):386-91 [11249724.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):813-22 [9989833.001]
  • [Cites] Physiol Rev. 2001 Jul;81(3):1269-304 [11427696.001]
  • [Cites] Diabetologia. 1999 Sep;42(9):1033-49 [10447513.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1020-7 [10713685.001]
  • [Cites] Lung Cancer. 2002 Jun;36(3):249-55 [12009233.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 10;293(3):1000-6 [12051759.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5286-93 [10537311.001]
  • [Cites] J Neurosci. 2002 Jan 1;22(1):103-13 [11756493.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14 ):4713-24 [11416147.001]
  • [Cites] Cancer Lett. 2001 Jul 26;168(2):125-32 [11403916.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1383-91 [9626454.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1053-7 [9734399.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 15):56-61 [11685730.001]
  • [Cites] Mol Cancer Ther. 2002 Mar;1(5):303-9 [12489846.001]
  • [Cites] J Bone Miner Res. 2001 Apr;16(4):625-38 [11315990.001]
  • [Cites] Gut. 2002 Oct;51(4):579-84 [12235084.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4292-302 [12409327.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):164-70 [9921989.001]
  • [Cites] FASEB J. 2002 Oct;16(12 ):1680-2 [12206994.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 6;732:42-50 [7978826.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1658-64 [10430065.001]
  • [Cites] Trends Genet. 1995 Feb;11(2):69-74 [7716810.001]
  • [Cites] Semin Hematol. 2002 Oct;39(4 Suppl 3):20-4 [12447848.001]
  • [Cites] Mol Cell Biol. 1987 Jun;7(6):2256-66 [3037355.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3344-52 [9699665.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5985-91 [11507039.001]
  • [Cites] Br J Pharmacol. 2001 Nov;134(5):1029-36 [11682451.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4525-30 [12036884.001]
  • [Cites] Breast Cancer Res Treat. 1996;38(1):75-83 [8825125.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):99-102 [9916799.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:9-15 [12202783.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S55-61 [11927289.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5566-70 [8971154.001]
  • [Cites] Oncogene. 1994 Mar;9(3):791-9 [8108121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12070-4 [9342364.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2895-900 [11712783.001]
  • [Cites] J Cell Physiol. 2001 Jul;188(1):120-31 [11382928.001]
  • [Cites] Prog Med Chem. 2002;40:23-62 [12516522.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1046-52 [9734398.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):24585-8 [7592678.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(2):155-65 [12186376.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Feb;80(2):239-56 [11897507.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3270-5 [12374698.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):387-97 [11485895.001]
  • [Cites] Carcinogenesis. 2000 Oct;21(10):1835-41 [11023541.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):44926-35 [11564733.001]
  • [Cites] Mol Cancer Ther. 2002 Jul;1(9):707-17 [12479367.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):101-13 [11467446.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):35-42 [9918200.001]
  • [Cites] Ann Oncol. 1999 Apr;10 (4):449-53 [10370788.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4614-7 [8062253.001]
  • [Cites] Oncogene. 1998 Aug 20;17(7):913-8 [9780008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98 (24):13681-6 [11717429.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6853-66 [10602461.001]
  • [Cites] Anal Biochem. 2001 Mar 1;290(1):126-37 [11180946.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):95-105 [10998351.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1722-33 [8657148.001]
  • [Cites] Oncogene. 1994 Dec;9(12):3601-8 [7970720.001]
  • [Cites] Oncology. 2002;63 Suppl 1:6-16 [12422050.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):36-9 [9020285.001]
  • [Cites] N Engl J Med. 1998 Nov 26;339(22):1609-18 [9828250.001]
  • [Cites] Oncogene. 1993 Apr;8(4):877-86 [8455942.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3544-50 [11705875.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1058-61 [9734400.001]
  • [Cites] Jpn J Cancer Res. 2002 Dec;93(12 ):1317-26 [12495471.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4652-61 [9377582.001]
  • [Cites] Mol Carcinog. 2002 Jun;34(2):72-7 [12112313.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):2905-27 [10579998.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):873-81 [12213581.001]
  • [Cites] Bioorg Med Chem Lett. 2000 Dec 18;10(24):2825-8 [11133101.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7184-8 [11585753.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6594-9 [11426644.001]
  • [Cites] J Biol Chem. 1994 Feb 18;269(7):5241-8 [8106507.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6770-8 [12438279.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7426-9 [11606375.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7883-90 [12420225.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):361-7 [12557142.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2188-92 [12114419.001]
  • [Cites] Cancer Res. 1981 Dec;41(12 Pt 1):5121-4 [6272989.001]
  • [Cites] Mol Cell Endocrinol. 2002 Aug 30;194(1-2):123-33 [12242035.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4743-58 [10519377.001]
  • [Cites] Cancer Res. 1979 Apr;39(4):1339-46 [421218.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):3977-82 [10632328.001]
  • [Cites] Biochem Soc Symp. 1999;64:29-48 [10207619.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:615-75 [11687500.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):6-13 [9662243.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92 (5):418-23 [10699072.001]
  • [Cites] Eur J Cancer. 1999 Nov;35(12):1717-23 [10674019.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(17):2194-8 [11677106.001]
  • [Cites] Anticancer Res. 1992 Jul-Aug;12(4):1147-53 [1386970.001]
  • [Cites] Carcinogenesis. 1999 Jun;20(6):1011-8 [10357781.001]
  • [Cites] Oncogene. 2001 Sep 6;20(39):5459-65 [11571643.001]
  • [Cites] Structure. 1998 Sep 15;6(9):1117-28 [9753691.001]
  • [Cites] Transplant Proc. 1997 Feb-Mar;29(1-2):1269-70 [9123300.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2726-35 [12039935.001]
  • [Cites] Int J Oncol. 1999 Aug;15(2):267-70 [10402236.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):391-401 [12538493.001]
  • [Cites] Biochim Biophys Acta. 1996 Jul 26;1302(2):93-109 [8695669.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jul;62(1):51-62 [10989985.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38349-52 [11533044.001]
  • [Cites] Mol Carcinog. 1996 Mar;15(3):215-26 [8597534.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):19-23 [10092503.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S19-26 [11927283.001]
  • [Cites] Kurume Med J. 2002;49(1-2):27-33 [12235869.001]
  • [Cites] Arch Biochem Biophys. 2002 Jul 15;403(2):209-18 [12139970.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14105-10 [9391160.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6376-80 [12438218.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):727-30 [8980174.001]
  • [Cites] J Antibiot (Tokyo). 1999 Dec;52(12):1086-94 [10695671.001]
  • [Cites] Nature. 1999 Apr 15;398(6728):630-4 [10217147.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2001;4(1):33-43 [12497061.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):11-21 [12138393.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):85-94 [12467226.001]
  • [Cites] Breast Cancer Res Treat. 1999 Mar;54(2):123-33 [10424403.001]
  • [Cites] Mol Carcinog. 2002 Aug;34(4):165-71 [12203367.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62 [12209125.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17 ):2272-8 [12441264.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;949:109-12 [11795342.001]
  • [Cites] Nature. 2000 Apr 13;404(6779):782-7 [10783894.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2750-6 [3102474.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):251-6 [10037172.001]
  • [Cites] Cell Growth Differ. 1996 Feb;7(2):243-50 [8822208.001]
  • [Cites] Bioorg Med Chem Lett. 2002 Oct 21;12(20):2893-7 [12270171.001]
  • [Cites] J Immunol. 2002 Dec 1;169(11):6490-7 [12444159.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5750-9 [12471041.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):731-40 [10216485.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):227-35 [11566614.001]
  • [Cites] Invasion Metastasis. 1992;12(3-4):168-84 [1284126.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16733-43 [11875070.001]
  • [Cites] Pathol Res Pract. 2000;196(12):817-26 [11156322.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4335-9 [12082622.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Dec;48(6):435-45 [11800023.001]
  • [Cites] J Biol Chem. 1995 May 26;270(21):12665-9 [7759517.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9827-32 [10449779.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):825-9 [11396171.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6549-56 [7987855.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2673-9 [10825140.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):525-30 [10688873.001]
  • [Cites] Exp Cell Res. 2001 Aug 1;268(1):84-92 [11461121.001]
  • [Cites] J Cell Physiol. 2000 Jun;183(3):301-13 [10797304.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):575-83 [12479217.001]
  • [Cites] Eur J Cancer. 1999 Jun;35(6):1014-9 [10533487.001]
  • [Cites] Neuron. 1995 May;14(5):927-39 [7748560.001]
  • [Cites] Blood. 2003 Jan 15;101(2):703-5 [12393542.001]
  • [Cites] Curr Opin Oncol. 1997 Nov;9(6):562-8 [9370078.001]
  • [Cites] Int J Oncol. 2000 Jan;16(1):65-73 [10601550.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5808-14 [10582703.001]
  • [Cites] FEBS Lett. 2001 Feb 16;490(3):153-62 [11223030.001]
  • [Cites] Immunopharmacology. 2000 May;47(2-3):185-201 [10878289.001]
  • [Cites] J Med Chem. 2001 Feb 1;44(3):429-40 [11462982.001]
  • [Cites] Cancer Lett. 2000 Jul 3;155(1):47-54 [10814878.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1996-2003 [11929816.001]
  • [Cites] J Natl Cancer Inst. 1980 May;64(5):1061-70 [6767871.001]
  • [Cites] Mol Cancer Ther. 2002 Sep;1(11):893-9 [12481410.001]
  • [Cites] Biochemistry (Mosc). 2000 Jan;65(1):59-67 [10702641.001]
  • [Cites] Oncology. 1999 Oct;57 Suppl 2:37-44 [10545801.001]
  • [Cites] Semin Hematol. 2002 Jul;39(3 Suppl 2):31-5 [12214291.001]
  • [Cites] FEBS Lett. 2002 Feb 13;512(1-3):334-40 [11852106.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6842-4 [10602459.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1753-8 [11742498.001]
  • [Cites] Trends Mol Med. 2001 Sep;7(9):395-400 [11530334.001]
  • [Cites] Semin Radiat Oncol. 2002 Jul;12(3 Suppl 2):27-32 [12174342.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3425-32 [11848504.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):533-8 [10502734.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):131-7 [11196150.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2101-3 [10786667.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6569-76 [11522656.001]
  • [Cites] J Cell Biochem. 2003 Jan 1;88(1):191-204 [12461788.001]
  • [Cites] Immunol Today. 1996 Apr;17(4):187-97 [8871351.001]
  • [Cites] Oral Oncol. 2002 Jul;38(5):468-74 [12110341.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 May;47(5):429-36 [11391859.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2427-33 [11290607.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 21;90(20):1552-8 [9790548.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):867-81 [11376107.001]
  • [Cites] Int J Cancer. 2000 Mar 20;89(2):177-86 [10754497.001]
  • [Cites] Oncol Rep. 2000 Nov-Dec;7(6):1377-81 [11032948.001]
  • [Cites] Cancer Treat Rev. 1999 Aug;25(4):229-35 [10448131.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6105-11 [11507060.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2249-53 [12369852.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):31-7 [12422311.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):256-62 [12432273.001]
  • [Cites] Oncogene. 2001 Nov 29;20(55):7925-34 [11753675.001]
  • [Cites] BMJ. 2002 Mar 23;324(7339):714-8 [11909790.001]
  • [Cites] Drugs. 2003;63(1):33-45 [12487621.001]
  • [Cites] Breast Cancer Res Treat. 1999 Feb;53(3):229-40 [10369069.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Br J Cancer. 2002 Mar 4;86(5):680-5 [11875725.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Biochem Pharmacol. 2001 Dec 1;62(11):1449-57 [11728381.001]
  • [Cites] FEBS Lett. 1999 Oct 22;460(1):145-8 [10571077.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3044-7 [12036911.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):6063-70 [10557095.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8887-95 [11751413.001]
  • [Cites] Pharmacol Ther. 2000 Dec;88(3):229-79 [11337027.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1065-72 [12006520.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):316-26 [12538484.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2637-45 [11135226.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):851-9 [11560954.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3696-704 [10999763.001]
  • [Cites] Curr Opin Investig Drugs. 2001 Aug;2(8):1070-6 [11892915.001]
  • [Cites] Annu Rev Biochem. 1995;64:621-51 [7574495.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12847-52 [12239347.001]
  • [Cites] Jpn J Cancer Res. 2000 Sep;91(9):886-92 [11011115.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(13):4794-8 [3523478.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18430-6 [11278744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Int J Oncol. 2001 Dec;19(6):1155-60 [11713584.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 22):4117-26 [11739643.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1519-28 [11121658.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Jun 4;11(11):1407-10 [11378365.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5405-7 [12359744.001]
  • [Cites] Breast Cancer Res. 2001;3(4):209-12 [11434870.001]
  • [Cites] Mol Cancer Res. 2002 Nov;1(1):32-47 [12496367.001]
  • [Cites] Med Res Rev. 2001 Nov;21(6):540-52 [11607934.001]
  • [Cites] Cancer Detect Prev. 2002;26(3):229-37 [12269771.001]
  • [Cites] Dig Dis Sci. 1998 Jul;43(7):1454-64 [9690379.001]
  • [Cites] Curr Opin Lipidol. 1997 Jun;8(3):159-66 [9211064.001]
  • [Cites] Nat Med. 1999 Jul;5(7):810-6 [10395327.001]
  • [Cites] Bioorg Med Chem Lett. 2002 Feb 11;12(3):423-5 [11814812.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):31099-106 [12048182.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5839-45 [8816498.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40888-95 [11527971.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5119-25 [12234971.001]
  • [Cites] J Immunol. 2002 Apr 15;168(8):3855-64 [11937539.001]
  • [Cites] J Biol Chem. 1998 Jul 17;273(29):18623-32 [9660836.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Nov 8;298(4):603-12 [12408995.001]
  • [Cites] J Natl Cancer Inst. 1999 Nov 3;91(21):1847-56 [10547391.001]
  • [Cites] Annu Rev Med. 2002;53:409-35 [11818483.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] J Immunother. 1999 Mar;22(2):155-65 [10093040.001]
  • [Cites] Cytometry. 2001 Apr 15;46(2):72-8 [11309815.001]
  • [Cites] Mol Cell Biol. 2001 Mar;21(6):2203-12 [11238953.001]
  • [Cites] JAMA. 1999 Jun 16;281(23):2189-97 [10376571.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98 (2):234-40 [11857414.001]
  • [Cites] Mol Cancer Ther. 2002 Aug;1(10):777-83 [12492110.001]
  • [Cites] Prostate. 2002 May 1;51(2):108-16 [11948965.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Nov;291(2):739-48 [10525095.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21 Suppl):47S-53S [11060327.001]
  • [Cites] Mol Cell Biol. 1990 Aug;10(8):4284-93 [2115124.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2563-72 [11489840.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34 [11106684.001]
  • [Cites] Anticancer Drugs. 2001 Sep;12(8):683-90 [11604556.001]
  • (PMID = 14587863.001).
  • [ISSN] 1083-3021
  • [Journal-full-title] Journal of mammary gland biology and neoplasia
  • [ISO-abbreviation] J Mammary Gland Biol Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Enzyme Inhibitors; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Estrogen; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 337
  •  go-up   go-down


17. Yan H, Blackburn AC, McLary SC, Tao L, Roberts AL, Xavier EA, Dickinson ES, Seo JH, Arenas RB, Otis CN, Cao QJ, Lawlor RG, Osborne BA, Kittrell FS, Medina D, Jerry DJ: Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. Am J Pathol; 2010 Mar;176(3):1421-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammary gland proliferation rates were similar in both BALB/c-Trp53+/- mice and wild-type controls.
  • In addition, sporadic mammary hyperplasias were rare in BALB/c-Trp53+/- mice and not detectably different from those of wild-type controls.
  • Transplantation of Trp53+/- ductal hyperplasias also indicated an association between loss of the wild-type allele of Trp53 and progression to invasive carcinomas.
  • Expression of biomarkers was retained when tumor fragments were transplanted to syngeneic hosts.
  • Overall, this panel of transplantable tumors provides a resource for detailed evaluation of the cell lineages undergoing transformation and preclinical testing of therapeutic agents targeting a variety of oncogenic pathways including cancer stem cells.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2004 Mar;34(3):726-34 [14991602.001]
  • [Cites] Trends Genet. 2004 Jun;20(6):235-43 [15145576.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3525-32 [15150107.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5140-7 [15289317.001]
  • [Cites] Cell. 1987 May 22;49(4):465-75 [3032456.001]
  • [Cites] Cell Growth Differ. 1990 Apr;1(4):161-70 [1707299.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2277-84 [1685017.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1269-74 [7731676.001]
  • [Cites] Anal Biochem. 1995 Mar 20;226(1):91-9 [7785785.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] Oncogene. 1997 Feb 20;14(7):865-71 [9047394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9648-53 [9275177.001]
  • [Cites] Carcinogenesis. 1998 Sep;19(9):1573-81 [9771927.001]
  • [Cites] Oncogene. 1998 Nov 5;17(18):2305-12 [9811461.001]
  • [Cites] J Pathol. 1999 Jul;188(3):237-44 [10419589.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):165-71 [15619621.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8166-73 [16166291.001]
  • [Cites] Cell Cycle. 2005 Dec;4(12):1808-16 [16294019.001]
  • [Cites] Development. 2006 Jan;133(2):363-9 [16368933.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5104-10 [16707433.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):1003-16 [16543940.001]
  • [Cites] Oncogene. 2006 Jun 8;25(24):3463-70 [16449974.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5906-11 [16998505.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):618-23 [17202265.001]
  • [Cites] Cell Res. 2007 Jan;17(1):42-9 [17211451.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1736-42 [17032926.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] Cancer Cell. 2007 Feb;11(2):103-5 [17292821.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5842-52 [17179143.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] Am J Pathol. 2007 Jun;170(6):2030-41 [17525270.001]
  • [Cites] Trends Cell Biol. 2007 Jun;17(6):286-91 [17481900.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6 [17626182.001]
  • [Cites] PLoS Biol. 2007 Aug;5(8):e201 [17676974.001]
  • [Cites] Stem Cell Rev. 2007 Jun;3(2):169-75 [17873349.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] Nat Cell Biol. 2008 Jun;10(6):676-87 [18454141.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4674-82 [18559513.001]
  • [Cites] Cell. 2008 Jul 11;134(1):62-73 [18614011.001]
  • [Cites] Breast Cancer Res. 2008;10(3):R43 [18471300.001]
  • [Cites] Neurobiol Aging. 2009 Mar;30(3):483-97 [17850928.001]
  • [Cites] Nature. 2009 Jul 23;460(7254):529-33 [19626115.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1052-8 [10713689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3444-9 [10716706.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1996 Jan;1(1):5-19 [10887477.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):2151-9 [11106587.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83-7 [11219776.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4621-8 [11498785.001]
  • [Cites] Nat Genet. 2002 May;31(1):55-9 [11967536.001]
  • [Cites] FASEB J. 2002 Jun;16(8):881-3 [11967232.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):289-98 [12086865.001]
  • [Cites] Mutat Res. 2003 Jan 28;522(1-2):69-83 [12517413.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):292-300 [12619115.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6140-3 [14559792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • (PMID = 20110418.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES015739; United States / NCI NIH HHS / CA / R01-CA105452; United States / NCI NIH HHS / CA / R01 CA095164; United States / NCI NIH HHS / CA / R01 CA105452; United States / NCI NIH HHS / CA / R01-CA095164; United States / NIEHS NIH HHS / ES / R01-ES015739
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Notch; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2832161
  •  go-up   go-down


18. King BL, Love SM, Rochman S, Kim JA: The Fourth International Symposium on the Intraductal Approach to Breast Cancer, Santa Barbara, California, 10-13 March 2005. Breast Cancer Res; 2005;7(5):198-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These approaches are being used to collect and analyze fluids and cells to develop methods for breast cancer detection and risk assessment; to introduce imaging technologies to explore the mammary tree for abnormalities; to administer therapeutic and/or preventive agents directly to the breast tissue; and to explore the biology of the normal mammary gland.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / physiopathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / physiopathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):99-105 [14999140.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1082-9 [15894656.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4442-52 [15231653.001]
  • [Cites] Breast J. 2004 Jul-Aug;10(4):271-2 [15239784.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(1):59-64 [15377851.001]
  • [Cites] Am J Surg. 2004 Oct;188(4):390-4 [15474432.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1510-7 [15494601.001]
  • [Cites] J Natl Cancer Inst. 1975 Apr;54(4):829-34 [1168727.001]
  • [Cites] Cancer. 1979 May;43(5):1788-99 [445368.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1550-4 [2418944.001]
  • [Cites] J Natl Cancer Inst. 1987 Nov;79(5):949-60 [3479643.001]
  • [Cites] J Clin Lab Anal. 2000;14(6):330-5 [11138618.001]
  • [Cites] Lancet. 2001 Apr 28;357(9265):1335-6 [11343741.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 7;93(21):1624-32 [11698566.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1791-8 [11734595.001]
  • [Cites] Breast Cancer Res. 2002;4(4):155-64 [12100741.001]
  • [Cites] Cancer. 2002 Aug 25;96(4):244-9 [12209667.001]
  • [Cites] Diagn Cytopathol. 2002 Nov;27(5):261-4; discussion 265 [12411988.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):690-4 [12548612.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1509-16 [12684427.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3029-33 [12912952.001]
  • [Cites] J Exp Zool A Comp Exp Biol. 2003 Nov 1;300(1):91-7 [14598391.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2170-6 [14601086.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):28-32 [14734448.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1073-80 [903989.001]
  • [Cites] Cancer Res. 1992 Jan 1;52(1):95-100 [1727390.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):130-41 [1536131.001]
  • [Cites] Breast Cancer Res Treat. 1998 Apr;48(3):211-9 [9598868.001]
  • [Cites] Cancer. 1958 Mar-Apr;11(2):377-409 [13511360.001]
  • [Cites] Cancer. 2004 Oct 25;102(5):322-7 [15376199.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):145-52 [15375011.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):149-57 [15692757.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):324-8 [15734953.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1686-91 [15572416.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):928-35 [15184248.001]
  • (PMID = 16168138.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1242146
  •  go-up   go-down


19. Thomas JL, Mack VL, Sun J, Terrell JR, Bucholtz KM: The functions of key residues in the inhibitor, substrate and cofactor sites of human 3beta-hydroxysteroid dehydrogenase type 1 are validated by mutagenesis. J Steroid Biochem Mol Biol; 2010 Jun;120(4-5):192-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The functions of key residues in the inhibitor, substrate and cofactor sites of human 3beta-hydroxysteroid dehydrogenase type 1 are validated by mutagenesis.
  • In postmenopausal women, human 3beta-hydroxysteroid dehydrogenase type 1 (3beta-HSD1) is a critical enzyme in the conversion of DHEA to estradiol in breast tumors, while 3beta-HSD2 participates in the production of cortisol and aldosterone in the human adrenal gland.
  • Dixon analyses of the inhibition of the R195P-1 mutant, P195R-2 mutant, wild-type 3beta-HSD1 and wild-type 3beta-HSD2 by trilostane has produced kinetic profiles that show inhibition of 3beta-HSD1 by trilostane (K(i)=0.10microM, competitive) with a 16-fold lower K(i) and different mode than measured for 3beta-HSD2 (K(i)=1.60microM, noncompetitive).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):16778-85 [14966133.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35483-90 [12832414.001]
  • [Cites] J Mol Endocrinol. 2004 Aug;33(1):253-61 [15291757.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Steroid Biochem. 1988 Nov;31(5):785-93 [3199818.001]
  • [Cites] J Steroid Biochem. 1989 Aug;33(2):209-17 [2770297.001]
  • [Cites] Mol Endocrinol. 1991 Aug;5(8):1147-57 [1944309.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Biochemistry. 1995 May 9;34(18):6003-13 [7742302.001]
  • [Cites] Biochemistry. 1996 Feb 27;35(8):2557-66 [8611559.001]
  • [Cites] J Endocrinol. 1996 Sep;150 Suppl:S189-207 [8943802.001]
  • [Cites] J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):267-71 [9365200.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):735-9 [9398055.001]
  • [Cites] J Steroid Biochem Mol Biol. 1998 Sep;66(5-6):327-34 [9749838.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):66-81 [9892013.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Sep;101(1):50-60 [16889958.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Oct;107(1-2):80-7 [17624763.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Jul;111(1-2):66-73 [18524572.001]
  • [Cites] Chem Biol Interact. 2009 Mar 16;178(1-3):94-8 [19027726.001]
  • [Cites] Mol Cell Endocrinol. 2009 Mar 25;301(1-2):174-82 [18955108.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25677-84 [11976334.001]
  • [Cites] Trends Endocrinol Metab. 2002 Aug;13(6):234-9 [12128283.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42795-801 [12205101.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 7;1654(2):123-43 [15172700.001]
  • (PMID = 20420909.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA114717-21; United States / NCI NIH HHS / CA / R01 CA114717; United States / NCI NIH HHS / CA / CA114717; United States / NCI NIH HHS / CA / R01 CA114717-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acids; 08J2K08A3Y / Dihydrotestosterone; 459AG36T1B / Dehydroepiandrosterone; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases; L0FPV48Q5R / trilostane
  • [Other-IDs] NLM/ NIHMS200209; NLM/ PMC2891085
  •  go-up   go-down


20. Delgado JS, Mustafi R, Yee J, Cerda S, Chumsangsri A, Dougherty U, Lichtenstein L, Fichera A, Bissonnette M: Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. Dig Dis Sci; 2008 Dec;53(12):3055-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This drug significantly reduced the up-regulations of cyclin D1, cyclin E, c-Myc, and Bcl-2 as well as the activation of STAT3 in SEG-1 cells.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Benzenesulfonates / pharmacology. Cell Proliferation / drug effects. Esophageal Neoplasms / pathology. Pyridines / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cyclin D1 / metabolism. Cyclin E / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Niacinamide / analogs & derivatives. Phenylurea Compounds. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. STAT3 Transcription Factor / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2007 May 1;73(9):1308-17 [17266941.001]
  • [Cites] Gut. 1989 Jan;30(1):14-8 [2920919.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4819-25 [14581353.001]
  • [Cites] Gastroenterology. 1984 Oct;87(4):927-33 [6468881.001]
  • [Cites] ANZ J Surg. 2007 Jan-Feb;77(1-2):37-9 [17295818.001]
  • [Cites] Dis Esophagus. 2007;20(3):212-6 [17509117.001]
  • [Cites] Oncol Rep. 1999 Jul-Aug;6(4):877-82 [10373674.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):664-72 [15763640.001]
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):307-13 [17123775.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7809-18 [14586407.001]
  • [Cites] Histopathology. 2001 Dec;39(6):589-96 [11903577.001]
  • [Cites] Gut. 2005 Mar;54 Suppl 1:i6-12 [15711008.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):824-37 [12081731.001]
  • [Cites] Surgery. 2004 Aug;136(2):160-8 [15300175.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3291-310 [17496923.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):75-87 [16947086.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6771-90 [16170185.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5656-64 [16740703.001]
  • [Cites] Anal Biochem. 2000 Oct 15;285(2):194-204 [11017702.001]
  • [Cites] EMBO J. 2000 Nov 1;19(21):5813-23 [11060032.001]
  • [Cites] Gut. 1991 Dec;32(12):1441-6 [1773946.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):212-5 [9040193.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3497-509 [10779339.001]
  • [Cites] BMC Cancer. 2007 Jun 08;7:97 [17559672.001]
  • [Cites] J Natl Med Assoc. 2007 Jun;99(6):620-6 [17595930.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G743-8 [15231484.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1377-82 [17487394.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2544-52 [16510571.001]
  • [Cites] Dis Esophagus. 2008;21(6):514-21 [18840136.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Feb 15;25(4):447-53 [17270000.001]
  • [Cites] Gut. 2003 Feb;52(2):174-80 [12524396.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G335-42 [16239404.001]
  • [Cites] J Surg Res. 2005 Jul 1;127(1):53-8 [15964304.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1028-32 [9672324.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3227-39 [17496918.001]
  • [Cites] JAMA. 2001 May 9;285(18):2331-8 [11343480.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11851-8 [17178882.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):379-88 [11331954.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5305-13 [17875759.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):631-4 [16731604.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 1):S2-6 [17449347.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004063 [17054195.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • (PMID = 18512153.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA036745; United States / NIDDK NIH HHS / DK / P30DK42086
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Cyclin E; 0 / MYC protein, human; 0 / Phenylurea Compounds; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / Pyridines; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 136601-57-5 / Cyclin D1; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


21. Park C, Yoo JH, Kim HJ, Lim CY, Kim JW, Lee SY, Kim JH, Jang JI, Park HM: Cyclosporine treatment of perianal gland adenoma concurrent with benign prostatic hyperplasia in a dog. Can Vet J; 2010 Nov;51(11):1279-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporine treatment of perianal gland adenoma concurrent with benign prostatic hyperplasia in a dog.
  • The nodules were diagnosed as perianal gland adenoma based on histopathologic examination.
  • After therapy with cyclosporin A for 5 wk, the perianal masses were moderately shrunken.
  • [MeSH-major] Adenoma / veterinary. Anal Gland Neoplasms / drug therapy. Cyclosporine / therapeutic use. Dog Diseases / drug therapy. Immunosuppressive Agents / therapeutic use
  • [MeSH-minor] Animals. Dogs. Hyperplasia / drug therapy. Hyperplasia / veterinary. Male. Prostate / drug effects. Prostate / pathology. Prostatic Diseases / drug therapy. Prostatic Diseases / veterinary. Treatment Outcome

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2001 Mar 5;193(5):607-20 [11238591.001]
  • [Cites] J Neurochem. 1997 Mar;68(3):1142-9 [9048760.001]
  • [Cites] Vet Dermatol. 2002 Apr;13(2):77-87 [11972891.001]
  • [Cites] J Am Vet Med Assoc. 2002 Aug 1;221(3):370-7 [12164533.001]
  • [Cites] J Am Vet Med Assoc. 2002 Apr 1;220(7):1009-16 [12420778.001]
  • [Cites] Vet Dermatol. 2003 Feb;14(1):1-9 [12603680.001]
  • [Cites] Vet Dermatol. 2003 Feb;14(1):11-22 [12603681.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Jun;284(6):C1593-603 [12734112.001]
  • [Cites] J Small Anim Pract. 2004 May;45(5):238-43 [15163050.001]
  • [Cites] Vet Rec. 1975 Dec 13;97(24):464-7 [173072.001]
  • [Cites] Cancer Res. 1977 Jul;37(7 Pt 1):2068-71 [861936.001]
  • [Cites] Aust Vet J. 2004 Nov;82(11):681-5 [15977612.001]
  • [Cites] J Am Vet Med Assoc. 2005 Jun 1;226(11):1855-63 [15934253.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Mar;46(3):782-90 [15728531.001]
  • [Cites] J Neurol. 1999 May;246(5):339-46 [10399863.001]
  • [Cites] Transplant Proc. 1998 Aug;30(5):2167-70 [9723430.001]
  • [Cites] Vet Surg. 1998 Jan-Feb;27(1):64-8 [9449179.001]
  • [Cites] J Am Vet Med Assoc. 1997 Nov 15;211(10):1249-53 [9373359.001]
  • [Cites] J Urol. 1987 Oct;138(4 Pt 2):991-5 [3656581.001]
  • [Cites] Can Vet J. 1997 Jan;38(1):39-41 [8993784.001]
  • [Cites] J Am Vet Med Assoc. 1996 Feb 15;208(4):517-9 [8603899.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2689-98 [7545467.001]
  • [Cites] Mol Cell Endocrinol. 1994 Feb;99(1):21-4 [8187957.001]
  • [Cites] Transplantation. 1992 Jan;53(1):190-5 [1310171.001]
  • [Cites] Am J Vet Res. 1988 Oct;49(10):1742-6 [3189991.001]
  • [Cites] Endocrinology. 1988 Aug;123(2):1069-74 [3396498.001]
  • [Cites] Res Vet Sci. 2006 Oct;81(2):231-6 [16427103.001]
  • [Cites] Vet Rec. 2001 May 26;148(21):662-3 [11400987.001]
  • (PMID = 21286331.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal = La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  • [Other-IDs] NLM/ PMC2957039
  •  go-up   go-down


22. Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N: Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol Metab; 2010 Nov;21(11):691-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although prolactin (PRL) is known as a survival factor that supports tumor growth and confers chemoresistance in both cancers, its precise role in these tumors has not been studied extensively.
  • Emphasis is placed on technological advances which enable high-throughput screening for small molecule inhibitors of PRLR signaling that could serve as oral medications.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Endocrinology. 2007 Jul;148(7):3089-101 [17412813.001]
  • [Cites] J Biol Chem. 2007 Nov 9;282(45):33118-31 [17785459.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):236-48 [18172316.001]
  • [Cites] Endocr Rev. 2008 Feb;29(1):1-41 [18057139.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):131-45 [18253708.001]
  • [Cites] BMC Biotechnol. 2008;8:11 [18254957.001]
  • [Cites] J Biol Chem. 2008 Jul 4;283(27):19085-94 [18467331.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(2):241-50 [17955362.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14533-8 [18779591.001]
  • [Cites] Breast Cancer Res. 2008;10(4):R68 [18681966.001]
  • [Cites] Bioorg Med Chem. 2009 Feb 1;17(3):1026-33 [18234500.001]
  • [Cites] Structure. 2009 Apr 15;17(4):489-98 [19368882.001]
  • [Cites] Carcinogenesis. 2009 Aug;30(8):1298-304 [19443905.001]
  • [Cites] Mod Pathol. 2009 Oct;22(10):1273-9 [19633648.001]
  • [Cites] Growth Horm IGF Res. 2002 Apr;12(2):126-36 [12175650.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Jan;95(1):271-9 [19897676.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3583-93 [10589775.001]
  • [Cites] Ann Surg Oncol. 2000 May;7(4):305-11 [10819372.001]
  • [Cites] Nat Struct Biol. 2000 Sep;7(9):808-15 [10966654.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33937-44 [10938266.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):767-77 [11159849.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26 [11259830.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1217-22 [11290538.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):463-5 [11291087.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6098-104 [11507059.001]
  • [Cites] J Endocrinol. 2001 Oct;171(1):R1-4 [11572805.001]
  • [Cites] Mol Hum Reprod. 2002 Jul;8(7):606-11 [12087074.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5047-55 [12140755.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1131-4 [12168912.001]
  • [Cites] Endocr Relat Cancer. 2010 Jun;17(2):R91-107 [20071456.001]
  • [Cites] Mol Cell Endocrinol. 2002 Nov 29;197(1-2):153-65 [12431808.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;973:454-8 [12485910.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):689-96 [12574200.001]
  • [Cites] Nat Rev Drug Discov. 2003 May;2(5):369-78 [12750740.001]
  • [Cites] Breast Cancer Res Treat. 2003 May;79(2):241-52 [12825859.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4664-74 [12879011.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4955-66 [12960074.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4666-73 [14581335.001]
  • [Cites] Curr Med Res Opin. 2004 Apr;20(4):533-40 [15119991.001]
  • [Cites] Mol Cell Endocrinol. 2004 May 31;220(1-2):109-23 [15196705.001]
  • [Cites] Lancet. 1976 Aug 7;2(7980):279-82 [59853.001]
  • [Cites] Cancer. 1977 Apr;39(4):1693-9 [856451.001]
  • [Cites] Am J Clin Pathol. 1985 Dec;84(6):687-96 [3878077.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Dec;24(12):1851-3 [3065085.001]
  • [Cites] Lab Invest. 1993 Mar;68(3):354-60 [8450651.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2591-5 [7780973.001]
  • [Cites] Cell Growth Differ. 1995 Apr;6(4):477-83 [7794815.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):3094-6 [7559904.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):639-69 [8969972.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):618-27 [9045863.001]
  • [Cites] Breast Cancer Res Treat. 1997 Jul;44(3):243-53 [9266104.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3692-9 [9360527.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5555-60 [9389544.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2744-51 [9389738.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):667-74 [9467590.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):202-11 [9583737.001]
  • [Cites] Endocr Rev. 1998 Aug;19(4):365-96 [9715372.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):863-70 [10079264.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):109-15 [15666390.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5863-8 [16115927.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Oct;15(10):1257-67 [16989600.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):571-81 [17024156.001]
  • [Cites] J Biomol Screen. 2006 Oct;11(7):864-9 [16973922.001]
  • [Cites] Growth Horm IGF Res. 2006 Oct-Dec;16(5-6):297-307 [17010651.001]
  • [Cites] Oncogene. 2006 Dec 7;25(58):7565-76 [16785991.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D298-300 [17135201.001]
  • [Cites] J Biol Chem. 2007 Feb 2;282(5):3262-72 [17130123.001]
  • [Cites] J Biol Chem. 2010 Mar 12;285(11):8422-33 [20053995.001]
  • [Cites] J Biol Chem. 2010 Mar 12;285(11):8003-12 [20080972.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):369-77 [19377875.001]
  • [Cites] Am J Pathol. 2010 Apr;176(4):1959-72 [20167868.001]
  • [Cites] Appl Microbiol Biotechnol. 2010 Jun;87(1):75-86 [20396881.001]
  • [Cites] Endocr Relat Cancer. 2010 Jun;17(2):481-93 [20233708.001]
  • [Cites] Anal Biochem. 2010 Aug;403(1-2):94-101 [20382104.001]
  • [Cites] J Biol Chem. 2010 Jun 25;285(26):20022-30 [20427283.001]
  • [Cites] Hum Reprod Update. 2007 Mar-Apr;13(2):121-41 [17068222.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1482-8 [17372279.001]
  • [Cites] Drugs. 2007;67(9):1329-41 [17547474.001]
  • (PMID = 20846877.001).
  • [ISSN] 1879-3061
  • [Journal-full-title] Trends in endocrinology and metabolism: TEM
  • [ISO-abbreviation] Trends Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES016803; United States / NCI NIH HHS / CA / R01 CA096613; United States / NCI NIH HHS / BC / Z01 BC005725; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NIEHS NIH HHS / ES / R21 ES016803; United States / NCI NIH HHS / CA / CA096613; United States / NIEHS NIH HHS / ES / P30 ES06096
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Prolactin
  • [Other-IDs] NLM/ NIHMS237492; NLM/ PMC2967606
  •  go-up   go-down


23. Khan IH, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung HJ, Luciw PA: Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells. Assay Drug Dev Technol; 2010 Feb;8(1):27-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accordingly, determination of both expression and activation (dimerization/heterodimerization and phosphorylation) of ErbB proteins is critical in defining their functional role in cancer.
  • Efficient and comprehensive methods to study molecular functions of ErbB family of RTKs are needed not only for improvements in diagnostics but also for early screening of targeted drugs (eg, small molecule inhibitors and therapeutic antibodies).
  • Importantly, the study provides proof-of-concept for the utility of the multiplex microbead immunoassay approach for potential use in efficient, robust, and rapid screening of drugs, particularly those targeting functional aspects of these potent signaling molecules.
  • [MeSH-major] Breast Neoplasms / enzymology. Protein Array Analysis / methods. Receptor Protein-Tyrosine Kinases / metabolism. Receptor, ErbB-2 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2002 Jul;2(7):828-38 [12124928.001]
  • [Cites] Adv Anat Embryol Cell Biol. 2007;190:1-65 [17432114.001]
  • [Cites] J Cell Physiol. 2003 Jan;194(1):13-9 [12447985.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12055-63 [12556529.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1274-83 [12684395.001]
  • [Cites] Proteomics. 2003 Jul;3(7):1128-44 [12872214.001]
  • [Cites] Anal Chem. 2004 May 15;76(10):2763-72 [15144186.001]
  • [Cites] Drug Discov Today. 2004 Oct 15;9(20):889-97 [15475322.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1532-42 [15480434.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2287-91 [1347947.001]
  • [Cites] EMBO J. 1997 Apr 1;16(7):1647-55 [9130710.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26954-61 [9756944.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(5):851-6 [17254832.001]
  • [Cites] Drugs. 2007;67(9):1329-41 [17547474.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):215-23 [18454306.001]
  • [Cites] Rapid Commun Mass Spectrom. 2005;19(1):57-71 [15570572.001]
  • [Cites] Histol Histopathol. 2005 Jul;20(3):1005-15 [15944951.001]
  • [Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S135-44 [16113090.001]
  • [Cites] Mol Cell Proteomics. 2006 Apr;5(4):758-68 [16369048.001]
  • [Cites] Breast Cancer Res Treat. 2006 Feb;95(3):211-8 [16261406.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16 [16829981.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):89-99 [16865534.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):3-11 [16947082.001]
  • [Cites] Adv Anat Pathol. 2006 Sep;13(5):263-9 [16998320.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1766(2):217-29 [17045403.001]
  • [Cites] Curr Med Chem. 2006;13(29):3483-92 [17168718.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7242-51 [17189395.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1487-93 [17308086.001]
  • [Cites] Curr Opin Biotechnol. 2002 Aug;13(4):315-20 [12323352.001]
  • (PMID = 20035613.001).
  • [ISSN] 1557-8127
  • [Journal-full-title] Assay and drug development technologies
  • [ISO-abbreviation] Assay Drug Dev Technol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA133209
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuregulin-1; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.10.1 / Receptor, ErbB-4
  • [Other-IDs] NLM/ PMC3196214
  •  go-up   go-down


24. Ren SG, Melmed S: Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion. Endocrinology; 2006 Aug;147(8):3936-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results indicate that pharmacological doses of PLP inhibit pituitary cell proliferation and hormone secretion, in part mediated through PLP-induced cell-cycle arrest and apoptosis.
  • Pyridoxine may therefore be appropriate for testing as a relatively safe drug for adjuvant treatment of hormone-secreting pituitary adenomas.

  • MedlinePlus Health Information. consumer health - B Vitamins.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1987 May;78(5):951-9 [3472003.001]
  • [Cites] Am J Clin Nutr. 1987 Oct;46(4):659-64 [3499066.001]
  • [Cites] Anticancer Res. 1988 Nov-Dec;8(6):1313-8 [3218963.001]
  • [Cites] J Clin Lab Anal. 1989;3(2):95-100 [2732845.001]
  • [Cites] J Biol Chem. 1990 Jul 25;265(21):12424-33 [2373699.001]
  • [Cites] J Biol Chem. 1992 Feb 25;267(6):3819-24 [1310983.001]
  • [Cites] J Nutr. 1995 Sep;125(9):2370-8 [7666255.001]
  • [Cites] Recent Prog Horm Res. 1996;51:189-215; discussion 215-6 [8701079.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):789-98 [9045884.001]
  • [Cites] Endocr Rev. 1997 Apr;18(2):206-28 [9101137.001]
  • [Cites] Nutr Cancer. 1997;28(2):206-11 [9290129.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1275-83 [9543156.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):684-92 [15870439.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):265-9 [15944799.001]
  • [Cites] J Nutr. 2001 Aug;131(8):2204-7 [11481418.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):3756-63 [11517151.001]
  • [Cites] Nutr Cancer. 2000;38(2):281-6 [11525607.001]
  • [Cites] Neoplasma. 2001;48(4):307-12 [11712684.001]
  • [Cites] J Steroid Biochem. 1986 Sep;25(3):359-65 [3773514.001]
  • [Cites] Nutr Cancer. 1985;7(1-2):43-52 [4070008.001]
  • [Cites] Neurology. 1985 Oct;35(10):1466-8 [2993949.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3116-26 [12069675.001]
  • [Cites] Urol Clin North Am. 2002 Feb;29(1):157-68 [12109342.001]
  • [Cites] J Nutr. 2002 Nov;132(11):3308-13 [12421844.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):499-508 [12579301.001]
  • [Cites] Nutr Cancer. 2002;43(2):152-8 [12588695.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 5;95(5):373-80 [12618502.001]
  • [Cites] Biochim Biophys Acta. 2003 Apr 11;1647(1-2):127-30 [12686121.001]
  • [Cites] Cancer Causes Control. 2003 Jun;14(5):477-84 [12946043.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1271-2 [14652294.001]
  • [Cites] Am J Clin Nutr. 2004 May;79(5):805-11 [15113718.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):819-23 [15492851.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Feb;40(2):256-9 [1117978.001]
  • [Cites] J Clin Endocrinol Metab. 1976 Mar;42(3):603-6 [1254699.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Jun;44(6):1197-9 [559690.001]
  • [Cites] Biomedicine. 1977 Jul;27(6):219-22 [20170.001]
  • [Cites] Biomedicine. 1978 Feb;29(1):13-5 [667280.001]
  • [Cites] Acta Endocrinol (Copenh). 1978 Oct;89(2):217-20 [358720.001]
  • [Cites] J Endocrinol Invest. 1979 Apr-Jun;2(2):117-24 [573769.001]
  • [Cites] J Clin Invest. 1980 Oct;66(4):688-95 [7419716.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Apr;54(4):872-5 [6801073.001]
  • [Cites] N Engl J Med. 1982 Aug 12;307(7):444-5 [7088124.001]
  • [Cites] J Inorg Biochem. 1982 Nov;17(3):185-203 [6757388.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Sep;47(3):689-90 [263321.001]
  • [Cites] N Engl J Med. 1983 Aug 25;309(8):445-8 [6308447.001]
  • [Cites] Horm Metab Res. 1985 Jan;17(1):46-7 [3967846.001]
  • (PMID = 16690808.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA 75979
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 12001-76-2 / Vitamin B Complex; 5V5IOJ8338 / Pyridoxal Phosphate; 9002-62-4 / Prolactin; 9002-72-6 / Growth Hormone
  • [Other-IDs] NLM/ NIHMS10630; NLM/ PMC1513048
  •  go-up   go-down


25. Rachagani S, Torres MP, Moniaux N, Batra SK: Current status of mucins in the diagnosis and therapy of cancer. Biofactors; 2009 Nov-Dec;35(6):509-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their nature and glycosylation content dictates the biochemical and biophysical properties of viscoelastic secretions, pointing out an important role in diverse biological functions, such as differentiation, cell adhesions, immune responses, and cell signaling.
  • Therefore, mucins can be used as valuable markers to distinguish between normal and disease conditions.
  • Indeed, this alteration in glycosylation patterns generates several epitopes in the oligosaccharide side chains that can be used as diagnostic and/or prognostic markers.
  • Furthermore, these characteristic tumor-associated epitopes are extensively used as appropriate immunotargets of malignant epithelial cells.
  • Therefore, in an effort to detect and treat cancer at the earliest stage possible, mucins are analyzed as potential markers of disease for diagnosis, progression, and for therapeutic purposes.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9561-6 [9083100.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Apr;16(4):471-8 [9115759.001]
  • [Cites] J Immunother. 1997 Jan;20(1):70-8 [9101416.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16398-403 [9195947.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):16873-83 [9201995.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):455-64 [9247464.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 8;238(1):143-8 [9299468.001]
  • [Cites] J Biol Chem. 1997 Sep 26;272(39):24198-202 [9305871.001]
  • [Cites] Fertil Steril. 1997 Oct;68(4):702-8 [9341614.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Nov;17(5):592-8 [9374110.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2783-92 [9389743.001]
  • [Cites] J Mol Evol. 1998 Jan;46(1):102-6 [9419229.001]
  • [Cites] J Pathol. 1997 Nov;183(3):311-7 [9422987.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):93-101 [9443988.001]
  • [Cites] J Hepatol. 1997 Dec;27(6):1057-66 [9453432.001]
  • [Cites] Am J Clin Pathol. 1998 Mar;109(3):302-8 [9495202.001]
  • [Cites] Pathol Int. 1997 Dec;47(12):813-30 [9503463.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):295-302 [9516914.001]
  • [Cites] Int J Cancer. 1998 Jun 10;76(6):817-23 [9626347.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jul;19(1):30-7 [9651178.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):357-62 [9663428.001]
  • [Cites] Clin Chem. 1998 Jul;44(7):1379-80 [9665412.001]
  • [Cites] Int J Oncol. 1998 Sep;13(3):481-7 [9683782.001]
  • [Cites] Cancer Immunol Immunother. 1998 Jul;46(5):245-52 [9690452.001]
  • [Cites] Forensic Sci Int. 2005 Aug 11;152(1):1-12 [15939171.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):881-9 [15958852.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2005 May 25;85(19):1333-8 [16029633.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7187s-7194s [16203820.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Clin Med Res. 2005 Nov;3(4):221-8 [16303887.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77 [16467101.001]
  • [Cites] BMC Gastroenterol. 2006;6:4 [16409634.001]
  • [Cites] J Histochem Cytochem. 2006 Mar;54(3):289-99 [16148312.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5910-8 [16740731.001]
  • [Cites] J Urol. 2006 Jul;176(1):91-5 [16753376.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Jul;35(1):95-102 [16514118.001]
  • [Cites] Breast Cancer Res. 2006;8(3):R27 [16776849.001]
  • [Cites] J Biol Chem. 2006 Aug 18;281(33):23676-85 [16737958.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Vaccine. 2007 Feb 19;25(9):1607-18 [17166639.001]
  • [Cites] World J Surg Oncol. 2007;5:31 [17349047.001]
  • [Cites] Curr Cancer Drug Targets. 2007 May;7(3):259-71 [17504123.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):883-92 [17360025.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4170-7 [17634545.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4652-4 [17671159.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4509-18 [17898272.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2007 Dec;51(4):304-13 [17464275.001]
  • [Cites] Laryngoscope. 2007 Sep;117(9):1666-76 [17667140.001]
  • [Cites] Glycobiology. 2008 Jan;18(1):74-83 [17977904.001]
  • [Cites] J Transl Med. 2007;5:60 [18039393.001]
  • [Cites] Biochem J. 2008 Mar 1;410(2):283-9 [17990980.001]
  • [Cites] Ann Hum Genet. 1987 Oct;51(Pt 4):289-94 [3447512.001]
  • [Cites] J Biol Chem. 1988 Sep 15;263(26):12820-3 [3417635.001]
  • [Cites] Pancreas. 1988;3(4):488-93 [3174610.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6480-7 [2703501.001]
  • [Cites] Bioessays. 1989 Apr;10(4):117-21 [2658987.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):1072-6 [2471698.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(18):7159-63 [2674949.001]
  • [Cites] Int J Cancer. 1989 Dec 15;44(6):985-9 [2481651.001]
  • [Cites] J Clin Lab Anal. 1989;3(6):370-7 [2482346.001]
  • [Cites] J Biol Chem. 1990 Apr 5;265(10):5573-8 [2318825.001]
  • [Cites] Eur J Biochem. 1990 May 20;189(3):463-73 [2351132.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Aug 31;171(1):407-15 [2393399.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15294-9 [2394722.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Dec 31;173(3):1019-29 [2268309.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):2908-16 [1709586.001]
  • [Cites] J Clin Invest. 1991 Sep;88(3):1005-13 [1885763.001]
  • [Cites] Am Rev Respir Dis. 1991 Sep;144(3 Pt 2):S15-8 [1892320.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1992;27(1-2):57-92 [1727693.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1954-60 [1372533.001]
  • [Cites] Int J Biol Markers. 1992 Jan-Mar;7(1):43-6 [1583347.001]
  • [Cites] Ann Genet. 1992;35(1):21-6 [1351710.001]
  • [Cites] Cancer Res. 1992 Oct 15;52(20):5663-7 [1394190.001]
  • [Cites] J Biol Chem. 1992 Oct 25;267(30):21375-83 [1400449.001]
  • [Cites] Annu Rev Physiol. 2008;70:431-57 [17850209.001]
  • [Cites] Annu Rev Physiol. 2008;70:459-86 [17850213.001]
  • [Cites] Exp Eye Res. 2008 Feb;86(2):403-11 [18184611.001]
  • [Cites] Curr Mol Med. 2008 Feb;8(1):12-37 [18289011.001]
  • [Cites] Cancer Biother Radiopharm. 2008 Feb;23(1):121-8 [18298336.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3060-9 [18483372.001]
  • [Cites] Mod Pathol. 2008 Jun;21(6):660-9 [18360351.001]
  • [Cites] Biochem J. 2008 Aug 1;413(3):545-52 [18426393.001]
  • [Cites] Proteomics. 2008 Aug;8(16):3329-41 [18651706.001]
  • [Cites] Int J Cancer. 2008 Oct 15;123(8):1848-53 [18661524.001]
  • [Cites] Lancet Oncol. 2008 Nov;9(11):1076-85 [19012856.001]
  • [Cites] J Dairy Sci. 2008 Dec;91(12):4477-83 [19038922.001]
  • [Cites] Biologicals. 2009 Jan;37(1):18-25 [18848467.001]
  • [Cites] Nucleic Acids Res. 2009 Feb;37(3):866-76 [19103663.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jun;58(6):977-87 [19023569.001]
  • [Cites] Cancer Invest. 2009 May;27(4):361-8 [19358018.001]
  • [Cites] Clin Lung Cancer. 2009 Mar;10 Suppl 1:S41-6 [19362946.001]
  • [Cites] Onkologie. 2009 May;32(5):238-44 [19420969.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jun;115(3):581-90 [18679793.001]
  • [Cites] Br J Cancer. 2009 Jun 2;100(11):1746-54 [19436292.001]
  • [Cites] Oncol Rep. 2009 Sep;22(3):649-57 [19639217.001]
  • [Cites] Carcinogenesis. 2009 Aug;30(8):1452-8 [19520792.001]
  • [Cites] Glycoconj J. 2009 Dec;26(9):1275-84 [19533339.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):953-64 [7657125.001]
  • [Cites] Cancer Immunol Immunother. 1995 Sep;41(3):185-92 [7553688.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):84-91 [8536891.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2237-44 [8625291.001]
  • [Cites] Biochem Soc Trans. 1995 Nov;23(4):840-5 [8654850.001]
  • [Cites] J Surg Res. 1996 Jun;63(1):298-304 [8667619.001]
  • [Cites] Biochem J. 1996 Jun 15;316 ( Pt 3):967-75 [8670177.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):560-4 [8813954.001]
  • [Cites] Glycoconj J. 1996 Oct;13(5):693-707 [8909996.001]
  • [Cites] Gastroenterology. 1996 Dec;111(6):1433-46 [8942721.001]
  • [Cites] J Pathol. 1996 Oct;180(2):160-5 [8976874.001]
  • [Cites] Genomics. 1996 Dec 15;38(3):340-52 [8975711.001]
  • [Cites] J Biol Chem. 1997 Feb 7;272(6):3168-78 [9013550.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):816-25 [9053509.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • [Cites] J Histochem Cytochem. 2000 Dec;48(12):1667-76 [11101635.001]
  • [Cites] Curr Pharm Des. 2000 Dec;6(18):1881-96 [11102566.001]
  • [Cites] BJU Int. 2001 Jan;87(1):39-46 [11121991.001]
  • [Cites] Biol Chem. 2001 Feb;382(2):143-9 [11308013.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18327-36 [11278439.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):97-106 [11391628.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] Breast Cancer Res Treat. 2001 May;67(1):15-22 [11518462.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):339-53 [11547902.001]
  • [Cites] Gut. 2001 Oct;49(4):544-51 [11559653.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1264-75 [11578957.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1245-55 [11578960.001]
  • [Cites] Front Biosci. 2001 Oct 1;6:D1192-206 [11578969.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2148-57 [11596032.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4033-40 [11751498.001]
  • [Cites] J Biochem. 2002 Jan;131(1):21-9 [11754731.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 1;291(3):466-75 [11855812.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):737-40 [11920644.001]
  • [Cites] Chest. 2002 May;121(5 Suppl):166S-182S [12010847.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 May;128(5):257-64 [12029441.001]
  • [Cites] Eur J Biochem. 2002 Jun;269(11):2755-63 [12047385.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • [Cites] Acta Otolaryngol. 2002 Jun;122(4):401-7 [12125997.001]
  • [Cites] Eur J Biochem. 2002 Aug;269(15):3637-44 [12153560.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Sep 29;250(3):757-61 [9784419.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30157-64 [9804771.001]
  • [Cites] J Infect Dis. 1998 Dec;178(6):1635-41 [9815215.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2605-14 [9829723.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5546-50 [9850092.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5662-6 [9865718.001]
  • [Cites] Glycoconj J. 1998 May;15(5):457-67 [9881747.001]
  • [Cites] J Clin Pathol. 1998 Sep;51(9):667-71 [9930070.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):210-8 [9935202.001]
  • [Cites] Glycobiology. 1999 Mar;9(3):293-302 [10024667.001]
  • [Cites] Inflamm Bowel Dis. 1999 Feb;5(1):24-32 [10028446.001]
  • [Cites] Biochem J. 1999 Mar 1;338 ( Pt 2):325-33 [10024507.001]
  • [Cites] Biochem J. 1999 Mar 1;338 ( Pt 2):507-13 [10024529.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Arch Biochem Biophys. 1999 Apr 15;364(2):286-93 [10190986.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Jul 22;261(1):83-9 [10405327.001]
  • [Cites] Ir J Med Sci. 1999 Apr-Jun;168(2):124-6 [10422394.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1918-24 [10430099.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:118-21 [10436801.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 5;263(3):728-36 [10512748.001]
  • [Cites] Scand J Gastroenterol. 1999 Sep;34(9):833-44 [10522599.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2240-5 [10521973.001]
  • [Cites] Acta Otolaryngol. 2005 Jan;125(1):76-81 [15799579.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Jul;31(1):86-91 [14988081.001]
  • [Cites] Mol Cancer. 2003 Jan 7;2:9 [12556240.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:4 [14711375.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):954-64 [15309883.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):1119-26 [15375564.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Sep;31(9):1443-6 [15446574.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4059-66 [15381683.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Digestion. 1978;17(3):234-63 [25218.001]
  • [Cites] Cancer Res. 1982 Feb;42(2):601-8 [7034925.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5489-92 [6193872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Aug;81(16):5242-6 [6591188.001]
  • [Cites] Int J Cancer. 1986 May 15;37(5):693-6 [3457770.001]
  • [Cites] Lab Invest. 1987 Aug;57(2):193-9 [3613527.001]
  • [Cites] Biochem Med Metab Biol. 1987 Dec;38(3):347-54 [3435684.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(7):2320-3 [2895474.001]
  • [Cites] Pathol Int. 2002 Jul;52(7):470-7 [12167106.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):154-69 [12218296.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1052-60 [12360467.001]
  • [Cites] Glycoconj J. 2001 Sep;18(9):661-84 [12386453.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 19;1573(3):394-405 [12417424.001]
  • [Cites] Cancer Immunol Immunother. 2002 Dec;51(11-12):669-73 [12439613.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Cornea. 2003 Jan;22(1):41-5 [12502947.001]
  • [Cites] Bioessays. 2003 Jan;25(1):66-71 [12508284.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2003 Jan;67(1):53-8 [12560150.001]
  • [Cites] Pathol Int. 2002 Nov;52(11):713-23 [12685548.001]
  • [Cites] J Clin Pathol. 2003 May;56(5):378-84 [12719460.001]
  • [Cites] Mod Pathol. 2003 May;16(5):403-10 [12748245.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3234-40 [12810653.001]
  • [Cites] Arch Soc Esp Oftalmol. 2003 Jul;78(7):375-81 [12898407.001]
  • [Cites] J Pathol. 1998 Dec;186(4):398-405 [10209489.001]
  • [Cites] J Exp Med. 2003 Dec 1;198(11):1623-6 [14638849.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1968-79 [14565953.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Feb;30(2):155-65 [12882755.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):150-7 [14657954.001]
  • [Cites] Biochim Biophys Acta. 2004 Feb 20;1676(3):240-50 [14984930.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):13174-82 [14764598.001]
  • [Cites] J Immunother. 2004 May-Jun;27(3):240-53 [15076142.001]
  • [Cites] Cancer Immunol Immunother. 1993;36(1):9-17 [8422670.001]
  • [Cites] Ann Hum Genet. 1992 Oct;56(Pt 4):281-7 [1362870.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5879-85 [7680650.001]
  • [Cites] Biochem J. 1993 Jul 15;293 ( Pt 2):329-37 [7916618.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(3-4):467-74 [8373999.001]
  • [Cites] J Biol Chem. 1993 Sep 25;268(27):20563-9 [7690757.001]
  • [Cites] J Immunol. 1993 Oct 1;151(7):3693-703 [7690810.001]
  • [Cites] J Histochem Cytochem. 1993 Oct;41(10):1479-85 [8245407.001]
  • [Cites] J Biol Chem. 1994 Jan 28;269(4):2440-6 [8300571.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):1054-61 [8143972.001]
  • [Cites] Br J Urol. 1994 Mar;73(3):256-62 [8162502.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2856-60 [7514493.001]
  • [Cites] Biochem J. 1994 Jun 1;300 ( Pt 2):295-8 [8002930.001]
  • [Cites] J Acquir Immune Defic Syndr. 1994 Oct;7(10):995-1002 [8083829.001]
  • [Cites] Gastroenterology. 1994 Nov;107(5):1352-63 [7926500.001]
  • [Cites] Cancer. 2009 Aug 1;115(15):3581-90 [19479974.001]
  • [Cites] Biochem J. 1995 Jan 1;305 ( Pt 1):211-9 [7826332.001]
  • [Cites] Bioessays. 1992 Sep;14(9):619-25 [1365918.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):255-65 [7698991.001]
  • [Cites] Crit Rev Immunol. 1994;14(3-4):293-309 [7538768.001]
  • [Cites] Annu Rev Physiol. 1995;57:607-34 [7778880.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] Anal Biochem. 1995 Apr 10;226(2):263-7 [7540808.001]
  • [Cites] Int J Biol Markers. 1995 Jan-Mar;10(1):24-9 [7629423.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35458-64 [12826677.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):301-6 [7927933.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • [Cites] Biochem J. 2000 Feb 1;345 Pt 3:557-64 [10642514.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):501-7 [10677310.001]
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):377-88 [10681391.001]
  • [Cites] Biochem J. 2000 Apr 1;347 Pt 1:37-44 [10727399.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1693-701 [10815887.001]
  • [Cites] Mol Biol Evol. 2000 Aug;17(8):1175-84 [10908637.001]
  • [Cites] J Biochem. 2000 Aug;128(2):233-43 [10920259.001]
  • [Cites] J Immunother. 2000 Sep-Oct;23(5):570-80 [11001550.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4017-25 [11051251.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3102-8 [11049990.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):507-18 [11058865.001]
  • [Cites] Gut. 2000 Dec;47(6):753-61 [11076872.001]
  • [ErratumIn] Biofactors. 2012 Nov-Dec;38(6):478
  • (PMID = 19904814.001).
  • [ISSN] 1872-8081
  • [Journal-full-title] BioFactors (Oxford, England)
  • [ISO-abbreviation] Biofactors
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA131944-02; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA133774; United States / NCI NIH HHS / CA / R01 CA131944-02; United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / R01 CA131944; United States / NCI NIH HHS / CA / CA78590; United States / NCI NIH HHS / CA / R01 CA133774; United States / NCI NIH HHS / CA / UO1 CA111294; United States / NCI NIH HHS / CA / CA131944
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers; 0 / Mucins
  • [Number-of-references] 258
  • [Other-IDs] NLM/ NIHMS187436; NLM/ PMC2846533
  •  go-up   go-down


26. Long JM, Bell CW, Fagg WS 4th, Kushman ME, Becker KG, McCubrey JA, Farwell MA: Microarray and pathway analysis reveals decreased CDC25A and increased CDC42 associated with slow growth of BCL2 overexpressing immortalized breast cell line. Cell Cycle; 2008 Oct;7(19):3062-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genes that were chosen for further analysis were confirmed by qRT-PCR, however, the western analysis did not always confirm differential expression of the proteins.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2001 Apr;15(4):515-22 [11368354.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4818-28 [11416155.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Med Hypotheses. 2002 Aug;59(2):170-9 [12208205.001]
  • [Cites] Schizophr Res. 2002 Nov 1;58(1):11-20 [12363385.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7765-75 [12420213.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):404-11 [16507464.001]
  • [Cites] Gene. 2006 Mar 15;369:7-19 [16446060.001]
  • [Cites] Free Radic Biol Med. 2006 Apr 1;40(7):1161-9 [16545683.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):177-86 [16319984.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1351-9 [16763616.001]
  • [Cites] J Cell Biochem. 2006 Sep 1;99(1):35-52 [16823799.001]
  • [Cites] Breast. 2006 Dec;15(6):718-27 [16675218.001]
  • [Cites] EMBO J. 2007 Mar 21;26(6):1624-36 [17332740.001]
  • [Cites] Mol Cancer. 2007;6:24 [17407548.001]
  • [Cites] Drug Resist Updat. 2007 Feb-Apr;10(1-2):13-29 [17303468.001]
  • [Cites] J Biol Chem. 2007 Jun 1;282(22):16585-98 [17389592.001]
  • [Cites] Cell Cycle. 2006 Nov 1;5(21):2440-2 [17106256.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28864-73 [17670745.001]
  • [Cites] Cell. 2003 Aug 8;114(3):323-34 [12914697.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):3-12 [14999149.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W20-5 [15215342.001]
  • [Cites] J Cell Biol. 2004 Jul 19;166(2):193-203 [15263017.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Nucleic Acids Res. 1981 Jan 10;9(1):133-48 [6163133.001]
  • [Cites] Genes Dev. 1987 Sep;1(7):645-58 [2962899.001]
  • [Cites] J Cell Biol. 1988 Jun;106(6):2159-70 [2454932.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] J Immunol. 1990 May 1;144(9):3602-10 [2184193.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2556-63 [8139558.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8940-4 [8090749.001]
  • [Cites] EMBO J. 1994 Sep 15;13(18):4302-10 [7523110.001]
  • [Cites] Genes Dev. 1994 Jul 15;8(14):1627-39 [7958844.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1270-2 [7652575.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4520-4 [7553620.001]
  • [Cites] J Biol Chem. 1995 Nov 3;270(44):26049-52 [7592801.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2219-26 [8642331.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):12695-8 [8663032.001]
  • [Cites] J Cell Biol. 1996 Jul;134(1):13-23 [8698809.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9545-52 [8790367.001]
  • [Cites] Oncogene. 1996 Oct 3;13(7):1511-9 [8875989.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):6979-90 [9003774.001]
  • [Cites] J Biol Chem. 1997 May 16;272(20):13229-35 [9148940.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Apr 28;233(3):781-7 [9168933.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):753-61 [9447971.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4012-22 [9632786.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):6379-95 [10454584.001]
  • [Cites] Cell Cycle. 2004 Jul;3(7):855-7 [15190208.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):137-47 [15619620.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5408-16 [15958590.001]
  • [Cites] BMC Genomics. 2005;6:75 [15907206.001]
  • [Cites] BMC Bioinformatics. 2005;6:144 [15941488.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1032-7 [16136080.001]
  • [Cites] Biochem Soc Trans. 2005 Nov;33(Pt 5):891-5 [16246005.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1527-31 [16273250.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D684-8 [16381959.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Cell Cycle. 2007 Dec 15;6(24):3039-42 [18073536.001]
  • [Cites] J Surg Res. 1998 Apr;76(1):22-6 [9695733.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):1903-10 [9788433.001]
  • [Cites] Mol Cell Biol. 1999 Jun;19(6):4390-404 [10330179.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Apr;4(2):153-64 [10426394.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5911-7 [10681583.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2651-9 [10825137.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(13):4745-53 [10848600.001]
  • [Cites] J Clin Invest. 2000 Sep;106(6):753-61 [10995786.001]
  • [Cites] J Cell Biol. 2000 Dec 25;151(7):1413-22 [11134071.001]
  • [Cites] Cell Death Differ. 2001 Jan;8(1):44-50 [11313702.001]
  • (PMID = 18838868.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098195; United States / Intramural NIH HHS / / Z01 AG000616-01; United States / NCI NIH HHS / CA / 1R15CA87810-01; United States / NCI NIH HHS / CA / R01CA098195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; EC 3.1.3.48 / cdc25 Phosphatases; EC 3.6.5.2 / cdc42 GTP-Binding Protein
  • [Other-IDs] NLM/ NIHMS79446; NLM/ PMC2634598
  •  go-up   go-down


27. Kut C, Mac Gabhann F, Popel AS: Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer; 2007 Oct 8;97(7):978-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.
  • Vascular endothelial growth factor (VEGF) is a major target for the inhibition of tumour vascularisation and the treatment of human cancer.
  • Many tumours produce large quantities of VEGF, and as a result, diagnosis and prognosis of cancer may be predicted by measuring changes in VEGF concentrations in blood.
  • In blood, the VEGF may be located in the plasma, or in the blood-borne cells and formed elements, in particular, platelets and leukocytes.
  • In this study, we collate the measurements of VEGF in platelets, leukocytes, plasma and serum for breast, prostate, colorectal and other cancers.
  • In addition, we analysed the concentration of VEGF in tumour tissue itself, as well as for other tissues in the human body.
  • Although the concentration of VEGF in tumours is high, the size of tumours is small compared to other tissues, in particular, skeletal muscle.
  • Thus, the total quantity of VEGF in tumours and in blood is small compared to the quantity in muscles.
  • This large reservoir of VEGF may have important implications for the treatment of cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2002 Jan-Feb;9(1):159-65 [11748475.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):14-8 [11857378.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):73-80 [11863115.001]
  • [Cites] Ann Med. 2004;36(4):273-7 [15224653.001]
  • [Cites] Intern Med J. 2004 Jun;34(6):310-5 [15228391.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):733-40 [15252843.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2912-8 [8504432.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):843-8 [8922199.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] J Surg Res. 1997 Feb 1;67(2):147-54 [9073561.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):455-8 [9291439.001]
  • [Cites] Cancer Lett. 1998 Mar 13;125(1-2):35-8 [9566693.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1279-85 [9607588.001]
  • [Cites] Obstet Gynecol. 1998 Sep;92(3):360-3 [9721770.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3129-36 [9738585.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):821-6 [9816236.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):647-51 [9815732.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 [9815613.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2451-8 [9815646.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2507-11 [9815654.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):178-87 [9921991.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):487-91 [10100697.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(2):161-6 [10326793.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):892-7 [10360671.001]
  • [Cites] Thorax. 1999 Aug;54(8):707-10 [10413724.001]
  • [Cites] Urology. 1999 Sep;54(3):523-7 [10475365.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2324-9 [10499600.001]
  • [Cites] Cancer Immunol Immunother. 1999 Oct;48(7):396-400 [10501853.001]
  • [Cites] Anesth Analg. 2005 Jan;100(1):244-9 [15616085.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):553-61 [15668703.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):584-93 [15701844.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1557-61 [15941972.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):874-9 [10543260.001]
  • [Cites] BJU Int. 2000 Feb;85(3):276-80 [10671881.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):812-7 [10732751.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1004-8 [10737380.001]
  • [Cites] Cancer Lett. 2000 May 29;153(1-2):7-12 [10779624.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:37-44 [10804090.001]
  • [Cites] Cancer Treat Rev. 2000 Jun;26(3):191-204 [10814561.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Acta Neuropathol. 2000 Jul;100(1):101-5 [10912927.001]
  • [Cites] Clin Exp Metastasis. 1999;17(8):687-94 [10919714.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3147-52 [10955796.001]
  • [Cites] Prostate. 2000 Sep 15;45(1):42-50 [10960841.001]
  • [Cites] Chest. 2000 Oct;118(4):948-51 [11035661.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1425-31 [11076648.001]
  • [Cites] Anal Bioanal Chem. 2005 Jun;382(4):1010-6 [15928947.001]
  • [Cites] Respirology. 2002 Jun;7(2):93-8 [11985729.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):393-406 [12013529.001]
  • [Cites] Surgery. 2002 May;131(5):548-55 [12019409.001]
  • [Cites] Eur J Cancer Prev. 2002 Jun;11(3):245-52 [12131658.001]
  • [Cites] Cancer Lett. 2002 Nov 8;185(1):31-7 [12142076.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5325-35 [12235003.001]
  • [Cites] Scand J Clin Lab Invest. 2002;62(5):343-50 [12387579.001]
  • [Cites] APMIS. 2002 Sep;110(9):646-50 [12529018.001]
  • [Cites] Clin Exp Metastasis. 2002;19(8):651-63 [12553370.001]
  • [Cites] Urology. 2003 Apr;61(4):765-9 [12670562.001]
  • [Cites] J Physiol. 2003 Jul 1;550(Pt 1):217-25 [12754306.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2416-25 [12855613.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2003 Jul;42(7):486-9 [12921610.001]
  • [Cites] Eur J Clin Invest. 2003 Oct;33(10):883-90 [14511360.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):535-40 [14520689.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4332-9 [14555503.001]
  • [Cites] Urol Res. 2003 Oct;31(5):335-40 [14574539.001]
  • [Cites] Eur Surg Res. 2003 Nov-Dec;35(6):492-6 [14593233.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2125-32 [14601081.001]
  • [Cites] J Appl Physiol (1985). 2004 Jan;96(1):19-24 [12949011.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R38-45 [14680499.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):244-50 [14734476.001]
  • [Cites] Cancer Lett. 2004 Feb 10;204(1):87-95 [14744538.001]
  • [Cites] Curr Pharm Des. 2004;10(1):11-26 [14754402.001]
  • [Cites] Acta Oncol. 2003;42(8):837-45 [14968945.001]
  • [Cites] Urology. 2004 Feb;63(2):327-32 [14972483.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2694-704 [15102673.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2941-55 [15126324.001]
  • [Cites] Angiogenesis. 2003;6(4):255-7 [15166493.001]
  • [Cites] Angiogenesis. 2003;6(4):283-7 [15166496.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] Wound Repair Regen. 2006 May-Jun;14(3):259-64 [16808804.001]
  • [Cites] PLoS Comput Biol. 2006 Sep 22;2(9):e127 [17002494.001]
  • [Cites] PLoS Comput Biol. 2006 Dec 29;2(12):e180 [17196035.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H459-74 [16980341.001]
  • [Cites] Mol Pathol. 2000 Dec;53(6):307-12 [11193049.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):227-35 [11176129.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):37-42 [11237490.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2533-6 [11289126.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2736-43 [11289156.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):538-43 [11297245.001]
  • [Cites] Neoplasia. 2001 Mar-Apr;3(2):143-53 [11420750.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1888-93 [11448901.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1932-6 [11448906.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5407-14 [11454684.001]
  • [Cites] Ann Surg Oncol. 2001 Oct;8(9):741-5 [11597016.001]
  • [Cites] Carcinogenesis. 2001 Nov;22(11):1765-73 [11698337.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3491-4 [11705867.001]
  • (PMID = 17912242.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL079653; United States / NHLBI NIH HHS / HL / R33 HL087351; United States / NHLBI NIH HHS / HL / HL079653; United States / NHLBI NIH HHS / HL / HL087351
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2360423
  •  go-up   go-down


28. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH: The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer; 2008 Apr 22;98(8):1380-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, RXR-selective ligands, also referred to as rexinoids, have been investigated as potential chemopreventive agents for breast cancer.
  • We also examined the regulation of a number of rexinoid-modulated genes including critical growth and cell cycle regulating genes using breast cell lines and mammary gland samples from mice treated with rexinoids.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Med (Berl). 1997 Jun;75(6):429-39 [9231883.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jul 18;236(2):294-8 [9240428.001]
  • [Cites] Genes Dev. 1997 Aug 15;11(16):2052-65 [9284045.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1658-64 [10430065.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4276-84 [10485472.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52643-52 [15448136.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):441-8 [15591091.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):13-22 [16413468.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):23-32 [16413469.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):147-57 [16273314.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1065-71 [16675486.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):12009-18 [17178900.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5488-96 [17875779.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6224-31 [17947490.001]
  • [Cites] J Natl Cancer Inst. 1999 Nov 3;91(21):1847-56 [10547391.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2118 [10601384.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):377-88 [10705921.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3696-704 [10999763.001]
  • [Cites] Oncogene. 2000 Dec 11;19(53):6130-7 [11156526.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 12;280(1):164-71 [11162494.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):240-1 [11158198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74 [12010861.001]
  • [Cites] Cancer. 2002 May 15;94(10):2766-92 [12173348.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3270-5 [12374698.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6376-80 [12438218.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46544-51 [12297495.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):296-300 [12559863.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16899-907 [12624110.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):20098-109 [12657651.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33 [14679152.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):715; author reply 715-6 [15126613.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3566-71 [15150113.001]
  • [Cites] Comp Med. 2004 Jun;54(3):280-7 [15253274.001]
  • [Cites] Proc Soc Exp Biol Med. 1983 Nov;174(2):270-5 [6227008.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • (PMID = 18362934.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA078480-02; United States / NCI NIH HHS / CA / R01 CA078480; United States / NCI NIH HHS / CA / R01 CA078480-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Bhlhe40 protein, mouse; 0 / Cyclin D; 0 / Cyclins; 0 / Homeodomain Proteins; 0 / Tetrahydronaphthalenes; A61RXM4375 / bexarotene
  • [Other-IDs] NLM/ NIHMS76206; NLM/ PMC2361704
  •  go-up   go-down


29. Brody JG, Tickner J, Rudel RA: Community-initiated breast cancer and environment studies and the precautionary principle. Environ Health Perspect; 2005 Aug;113(8):920-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The exposure studies are key because they are critical in assessing plausibility (without exposure to a causal agent, there is no health effect), are prerequisite to health studies, and identify preventable exposures that could be reduced by precautionary policies, even in the absence of strong evidence of harm.
  • The breast cancer studies have contributed to environmental and biological sampling programs for endocrine-disrupting compounds in drinking water and household air and dust and the application of geographic information systems for surveillance and historical exposure assessment.
  • [MeSH-major] Breast Neoplasms / etiology. Consumer Participation. Environmental Exposure. Research Design

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 2000 Dec;108(12):A559-65 [11133418.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2003 Sep;13(5):403-16 [12973368.001]
  • [Cites] J Air Waste Manag Assoc. 2001 Apr;51(4):499-513 [11321907.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):871-6 [11673114.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1340-2 [11684218.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Jan-Feb;12(1):64-80 [11859434.001]
  • [Cites] Science. 2003 Oct 24;302(5645):643-6 [14576434.001]
  • [Cites] Environ Sci Technol. 2003 Oct 15;37(20):4543-53 [14594359.001]
  • [Cites] Environ Sci Technol. 2003 Nov 1;37(21):407A-411A [14620805.001]
  • [Cites] Ann Epidemiol. 2004 Feb;14(2):89-94 [15018880.001]
  • [Cites] Environ Health Perspect. 2004 Jun;112(8):889-97 [15175178.001]
  • [Cites] Epidemiology. 2004 Sep;15(5):529-35 [15308951.001]
  • [Cites] Environ Health Perspect. 1993 Oct;101(5):372-7 [8119245.001]
  • [Cites] Environ Health Perspect. 1995 Oct;103 Suppl 7:113-22 [8593856.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:573-96 [8725402.001]
  • [Cites] Public Health Rep. 1996 Nov-Dec;111(6):494-507 [8955694.001]
  • [Cites] Int J Health Serv. 2004;34(4):625-46 [15560426.001]
  • [Cites] Am J Public Health. 2002 Apr;92(4):611-3 [11919060.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):909-19 [11918907.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):3-15 [12160084.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):677-85 [12163319.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):686-97 [12163320.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):222-9 [12491485.001]
  • [Cites] Public Health Rep. 2002 Nov-Dec;117(6):521-33 [12576532.001]
  • [Cites] Public Health Rep. 2002 Nov-Dec;117(6):534-45 [12576533.001]
  • [Cites] Environ Health Perspect. 2003 Jun;111(8):1007-19 [12826474.001]
  • [Cites] Epidemiology. 2003 Jul;14(4):386-91 [12843760.001]
  • [Cites] Environ Health Perspect. 2001 Mar;109 Suppl 1:35-47 [11250804.001]
  • (PMID = 16079059.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1280329
  •  go-up   go-down


30. Kampa M, Alexaki VI, Notas G, Nifli AP, Nistikaki A, Hatzoglou A, Bakogeorgou E, Kouimtzoglou E, Blekas G, Boskou D, Gravanis A, Castanas E: Antiproliferative and apoptotic effects of selective phenolic acids on T47D human breast cancer cells: potential mechanisms of action. Breast Cancer Res; 2004;6(2):R63-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative and apoptotic effects of selective phenolic acids on T47D human breast cancer cells: potential mechanisms of action.
  • In addition to polyphenols, phenolic acids, found at high concentrations in a number of plants, possess antioxidant action.
  • The main phenolic acids found in foods are derivatives of 4-hydroxybenzoic acid and 4-hydroxycinnamic acid.
  • The antioxidative activity of these phenolic acids in T47D cells does not coincide with their inhibitory effect on tumoral proliferation.
  • Both agents induce apoptosis via the Fas/FasL system.
  • CONCLUSIONS: Phenolic acids exert a direct antiproliferative action, evident at low concentrations, comparable with those found in biological fluids after ingestion of foods rich in phenolic acids.
  • Furthermore, the direct interaction with the aryl hydrocarbon receptor, the nitric oxide synthase inhibition and their pro-apoptotic effect provide some insights into their biological mode of action.
  • [MeSH-major] Apoptosis / drug effects. Breast Neoplasms / metabolism. Cell Proliferation / drug effects. Hydroxybenzoates / pharmacology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Humans. Receptors, Aryl Hydrocarbon / metabolism. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):902-6 [11093812.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5272-5 [7585587.001]
  • [Cites] Nutr Cancer. 2000;37(2):223-33 [11142097.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):257-69 [11174847.001]
  • [Cites] Toxicol Lett. 2001 Mar 31;120(1-3):1-7 [11323156.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3902-7 [11358803.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6120-30 [11507062.001]
  • [Cites] Biochem Pharmacol. 2001 Oct 15;62(8):1113-24 [11597580.001]
  • [Cites] FASEB J. 2001 Nov;15(13):2345-54 [11689460.001]
  • [Cites] Nutrition. 2002 Jan;18(1):75-81 [11827770.001]
  • [Cites] Mol Pharmacol. 1999 Oct;56(4):784-90 [10496962.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):31353-7 [8537407.001]
  • [Cites] Food Chem Toxicol. 1999 Sep-Oct;37(9-10):937-42 [10541448.001]
  • [Cites] Biochem Pharmacol. 2000 Jan 1;59(1):65-85 [10605936.001]
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):37679-84 [10608825.001]
  • [Cites] Biochem Pharmacol. 2000 Apr 15;59(8):997-1005 [10692565.001]
  • [Cites] J Cell Biochem. 2000 Jun 6;78(3):429-41 [10861841.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24780-7 [11959854.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Sep;283(3):C831-8 [12176740.001]
  • [Cites] Chem Biol Interact. 2002 Sep 20;141(1-2):97-115 [12213387.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1358-63 [12599246.001]
  • [Cites] J Nutr Biochem. 2003 Feb;14(2):64-73 [12667597.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jul;5(3):295-306 [14973392.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Crit Rev Food Sci Nutr. 1989;28(4):315-47 [2690858.001]
  • [Cites] Science. 1991 May 17;252(5008):954-8 [1852076.001]
  • [Cites] Science. 1992 May 22;256(5060):1193-5 [1317062.001]
  • [Cites] Biochem Pharmacol. 1993 Mar 9;45(5):1129-36 [8384853.001]
  • [Cites] J Biol Chem. 1993 Jun 15;268(17):12231-4 [7685338.001]
  • [Cites] Anal Biochem. 1993 May 15;211(1):102-12 [8323021.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):2002-12 [7504210.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2707-13 [8168101.001]
  • [Cites] Biochem Pharmacol. 1994 Aug 30;48(5):923-36 [8093105.001]
  • [Cites] Carcinogenesis. 1994 Oct;15(10):2347-52 [7955076.001]
  • [Cites] J Immunol Methods. 1995 Jul 17;184(1):39-51 [7622868.001]
  • [Cites] FEBS Lett. 1995 Aug 7;369(2-3):131-5 [7649244.001]
  • [Cites] J Biol Chem. 1996 Mar 15;271(11):6144-51 [8626402.001]
  • [Cites] Free Radic Biol Med. 1996;20(7):933-56 [8743980.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5865-75 [8927054.001]
  • [Cites] J Biol Chem. 1997 Feb 14;272(7):4451-7 [9020169.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8581-93 [9079689.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 17;232(2):328-31 [9125174.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4273-8 [9113979.001]
  • [Cites] Carcinogenesis. 1997 May;18(5):925-33 [9163677.001]
  • [Cites] Mol Carcinog. 1997 Jun;19(2):101-13 [9210957.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):4933-47 [9271372.001]
  • [Cites] Life Sci. 1998;62(6):541-6 [9464466.001]
  • [Cites] Mol Pharmacol. 1998 Mar;53(3):438-45 [9495809.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):711-21 [9635855.001]
  • [Cites] Life Sci. 1998;63(23):2097-105 [9839533.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5707-12 [9865727.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1340-6 [10188874.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1561-6 [10426807.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22155-64 [10428779.001]
  • [Cites] Oncogene. 2000 Nov 16;19(48):5498-506 [11114727.001]
  • (PMID = 14979919.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxybenzoates; 0 / Receptors, Aryl Hydrocarbon; 29656-58-4 / phenolic acid
  • [Other-IDs] NLM/ PMC400651
  •  go-up   go-down


31. Hille A, Ott I, Kitanovic A, Kitanovic I, Alborzinia H, Lederer E, Wölfl S, Metzler-Nolte N, Schäfer S, Sheldrick WS, Bischof C, Schatzschneider U, Gust R: [N,N'-Bis(salicylidene)-1,2-phenylenediamine]metal complexes with cell death promoting properties. J Biol Inorg Chem; 2009 Jun;14(5):711-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We developed N,N'-bis(salicylidene)-1,2-phenylenediamine (salophene, 1) as a chelating agent for metal ions such as Mn(II/III), Fe(II/III), Co(II), Ni(II), Cu(II), and Zn(II).
  • Both complexes possessed high activity against various tumor cells, for instance, MDA-MB-231 mammary carcinoma cells as well as HT-29 colon carcinoma cells.
  • [MeSH-major] Apoptosis / drug effects. Chelating Agents / chemistry. Chelating Agents / pharmacology. Metals / chemistry. Salicylates / chemistry. Salicylates / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Animals. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Cattle. Cell Line, Tumor. Circular Dichroism. Colonic Neoplasms / drug therapy. DNA / metabolism. Electric Impedance. Female. Humans. Oxidation-Reduction. Oxygen Consumption / drug effects. Reactive Oxygen Species / metabolism. Thymus Gland / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathophysiology. 2000 Sep;7(3):153-163 [10996508.001]
  • [Cites] J Med Chem. 2004 Nov 18;47(24):5837-46 [15537341.001]
  • [Cites] Inorg Chem. 1996 Aug 14;35(17):4837-4847 [11666683.001]
  • [Cites] Curr Med Chem. 2005;12(10):1161-208 [15892631.001]
  • [Cites] Biosens Bioelectron. 1997;12(1):29-41 [8976050.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(1):35-43 [1309532.001]
  • [Cites] ChemMedChem. 2007 Dec;2(12):1723-9 [17943711.001]
  • [Cites] Mol Cell Biochem. 2004 Nov;266(1-2):37-56 [15646026.001]
  • [Cites] J Fluoresc. 2005 Jan;15(1):13-9 [15711872.001]
  • [Cites] Fresenius J Anal Chem. 2001 Jan 1;369(1):30-5 [11210226.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):37-43 [7596430.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):798-812 [9404652.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):347-57 [17383100.001]
  • [Cites] Chem Commun (Camb). 2007 Nov 28;(44):4565-79 [17989802.001]
  • [Cites] J Inorg Biochem. 1996 Jun;62(4):281-98 [8676105.001]
  • [Cites] J Cancer Res Clin Oncol. 1988;114(4):347-58 [3410875.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33533-9 [9837934.001]
  • [Cites] Nature. 1992 Mar 26;356(6367):356-8 [1549180.001]
  • [Cites] J Am Chem Soc. 2005 Aug 10;127(31):10869-78 [16076192.001]
  • [Cites] Chem Soc Rev. 2003 Jul;32(4):215-24 [12875027.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):346-7 [8090205.001]
  • [Cites] Chem Rev. 1999 Sep 8;99(9):2777-96 [11749500.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1558-77 [15073842.001]
  • [Cites] Chem Rev. 2001 Jan;101(1):37-52 [11712193.001]
  • [Cites] J Med Chem. 2002 Sep 26;45(20):4549-58 [12238934.001]
  • [Cites] Cell. 1995 Jun 2;81(5):801-9 [7774019.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Apr 1;220(1):33-44 [17320130.001]
  • [Cites] Anal Biochem. 1990 Jun;187(2):262-7 [2382827.001]
  • [Cites] Chemistry. 2005 Aug 5;11(16):4743-50 [15912543.001]
  • [Cites] Methods Enzymol. 1990;186:1-85 [2172697.001]
  • [Cites] Biochem J. 1997 Aug 15;326 ( Pt 1):1-16 [9337844.001]
  • (PMID = 19259708.001).
  • [ISSN] 1432-1327
  • [Journal-full-title] Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry
  • [ISO-abbreviation] J. Biol. Inorg. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Metals; 0 / Reactive Oxygen Species; 0 / Salicylates; 118-57-0 / salophen; 9007-49-2 / DNA
  •  go-up   go-down


32. Michimukai E, Kitamura N, Zhang Y, Wang H, Hiraishi Y, Sumi K, Hayashido Y, Toratani S, Okamoto T: Mutations in the human homologue of the Drosophila segment polarity gene patched in oral squamous cell carcinoma cell lines. In Vitro Cell Dev Biol Anim; 2001 Jul-Aug;37(7):459-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we have analyzed tumor deoxyribonucleic acid from oral squamous cell carcinoma (OSCC) cells for patched mutations using an exon-by-exon single strand conformation polymorphism assay and direct sequencing.
  • We found two missense mutations which affected the conserved residue in the transmembrane domains of the gene product and in the intracellular loop at the C-terminal residue implicated in regulating the smoothened molecule.
  • In addition, we demonstrated that the N-terminal fragment of sonic hedgehog (Shh-N) stimulates the growth of normal epithelial cells, the OSCC cell line, NA, and the salivary gland adenocarcinoma cell lines, HSG and HSY, which have no detectable mutation in patched.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. DNA, Neoplasm / analysis. Membrane Proteins / genetics. Mouth Neoplasms / genetics. Mutation
  • [MeSH-minor] Cell Division / drug effects. Culture Media, Serum-Free. DNA Mutational Analysis. Epithelial Cells / drug effects. Hedgehog Proteins. Humans. Mutation, Missense. Patched Receptors. Peptide Fragments / pharmacology. Polymorphism, Single-Stranded Conformational. RNA, Messenger / analysis. Receptors, Cell Surface. Sequence Analysis, DNA. Signal Transduction. Trans-Activators / pharmacology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] J Oral Pathol Med. 1994 Nov;23(10):451-6 [7532220.001]
  • [Cites] Oncogene. 1997 Jul 17;15(3):361-6 [9233770.001]
  • [Cites] Nat Genet. 1996 Sep;14 (1):7-8 [8782809.001]
  • [Cites] Nature. 1980 Oct 30;287(5785):795-801 [6776413.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Trends Cell Biol. 1997 Nov;7(11):442-6 [17709003.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 18;238(2):658-64 [9299570.001]
  • [Cites] Nat Genet. 1996 Sep;14 (1):78-81 [8782823.001]
  • [Cites] EMBO J. 1998 Jul 1 ;17 (13):3505-11 [9649421.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):176-9 [8906794.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;51(3):187-95 [2426861.001]
  • [Cites] Cell. 1994 Feb 25;76(4):761-75 [8124714.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1184-8 [7584992.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4677-81 [9354420.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1417-30 [7916661.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16778-85 [1885605.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • [Cites] Mol Med Today. 1998 Aug;4(8):343-9 [9755453.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):876-81 [9349822.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Science. 1994 Dec 2;266(5190):1528-37 [7985023.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Feb;74(2):565-9 [265522.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Trends Genet. 1997 Jan;13(1):14-21 [9009843.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1401-16 [8269518.001]
  • [Cites] In Vitro Cell Dev Biol. 1988 Aug;24(8):753-8 [3045071.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):745-52 [7248901.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Feb;31(2):84-6 [7735570.001]
  • [Cites] Cell. 1995 Feb 24;80(4):517-20 [7867057.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1103-9 [9262247.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(15):5698-702 [3165197.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Mar;21(3):276-9 [9523206.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):113-25 [7712637.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • (PMID = 11573822.001).
  • [ISSN] 1071-2690
  • [Journal-full-title] In vitro cellular & developmental biology. Animal
  • [ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Culture Media, Serum-Free; 0 / DNA, Neoplasm; 0 / Hedgehog Proteins; 0 / Membrane Proteins; 0 / Patched Receptors; 0 / Peptide Fragments; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators
  •  go-up   go-down


33. van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE: Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer; 2006;6:86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment.
  • BACKGROUND: Sensitivity of breast tumors to anticancer drugs depends upon dynamic interactions between epithelial tumor cells and their microenvironment including stromal cells and extracellular matrix.
  • To study drug-sensitivity within different compartments of an individual tumor ex vivo, culture models directly established from fresh tumor tissues are absolutely essential.
  • METHODS: We prepared 0.2 mm thick tissue slices from freshly excised tumor samples and cultivated them individually in the presence or absence of taxol for 4 days.
  • RESULTS: We obtained a mean of 49 tissue slices from 22 breast cancer specimens allowing a wide range of experiments in each individual tumor.
  • A three-color fluorescence viability assay enabled a rapid and authentic estimation of cell viability in the different tumor compartments within non-fixed tissue slices.
  • CONCLUSION: We describe a tissue culture method combined with a novel read out system for both tissue cultivation and rapid assessment of drug efficacy together with the simultaneous identification of different cell types within non-fixed breast cancer tissues.
  • This method has potential significance for studying tumor responses to anticancer drugs in the complex environment of a primary cancer tissue.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Drug Screening Assays, Antitumor / methods. Paclitaxel / pharmacology
  • [MeSH-minor] Adenosine Triphosphate / analysis. Apoptosis / drug effects. Cell Division / drug effects. Cell Survival. DNA, Neoplasm / analysis. Female. Humans. Microscopy, Confocal. Microscopy, Fluorescence. Tumor Cells, Cultured / chemistry. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 1998;194(3):177-81 [9587936.001]
  • [Cites] Physiol Rev. 1996 Jan;76(1):69-125 [8592733.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Apr;4(2):193-201 [10426398.001]
  • [Cites] Mol Cell Neurosci. 2005 Jan;28(1):42-54 [15607940.001]
  • [Cites] Toxicol Sci. 2005 Feb;83(2):257-63 [15525692.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):627-36 [15818402.001]
  • [Cites] Methods Mol Med. 2005;110:101-20 [15901931.001]
  • [Cites] Biotechnol Prog. 2005 Jul-Aug;21(4):1289-96 [16080713.001]
  • [Cites] Endocr Relat Cancer. 2000 Jun;7(2):95-113 [10903527.001]
  • [Cites] Breast Cancer Res. 2001;3(4):218-23 [11434872.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):186-94 [11774263.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):205-16 [12242153.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • [Cites] Breast Cancer Res. 2003;5(2):89-95 [12631387.001]
  • [Cites] J Cell Sci. 2003 Jun 15;116(Pt 12):2377-88 [12766184.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):169-72 [12962682.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1789-95 [14583785.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1751-6 [14996736.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jun;85(3):281-91 [15111767.001]
  • [Cites] Oncol Rep. 2004 Jul;12(1):85-90 [15201964.001]
  • [Cites] Neoplasma. 1967;14(5):507-19 [5583355.001]
  • [Cites] Anal Biochem. 1980 May 1;104(1):118-23 [6770714.001]
  • [Cites] Biomed Biochim Acta. 1983;42(7-8):907-16 [6316948.001]
  • [Cites] Ann N Y Acad Sci. 1986;464:58-65 [2942075.001]
  • [Cites] Cancer Drug Deliv. 1987;4(2):63-74 [3427553.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):78-83 [2293560.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Nat Med. 1999 Jun;5(6):662-8 [10371505.001]
  • (PMID = 16603054.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 8L70Q75FXE / Adenosine Triphosphate; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1456977
  •  go-up   go-down


34. Kothari MS, Ali S, Buluwela L, Livni N, Shousha S, Sinnett HD, Vashisht R, Thorpe P, Van Noorden S, Coombes RC, Slade MJ: Purified malignant mammary epithelial cells maintain hormone responsiveness in culture. Br J Cancer; 2003 Apr 7;88(7):1071-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, ERalpha and progesterone receptor (PR) expression is maintained in malignant cells, whereas normal epithelial cells rapidly lose ERalpha and PR.
  • [MeSH-major] Breast / drug effects. Breast Neoplasms / pathology. Estradiol / pharmacology
  • [MeSH-minor] Cell Separation. Cell Survival / drug effects. Epithelial Cells / drug effects. Female. Humans. Mammography. Tamoxifen / pharmacology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12589-94 [10535966.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35684-92 [11473106.001]
  • [Cites] Cell Tissue Res. 2003 Feb;311(2):217-26 [12596041.001]
  • [Cites] Nature. 1967 Oct 14;216(5111):173-4 [4862079.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5748-51 [3664479.001]
  • [Cites] J Clin Pathol. 1990 Mar;43(3):213-9 [1692040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7360-4 [2217169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5 [1351679.001]
  • [Cites] Cell Growth Differ. 1992 Jun;3(6):335-45 [1419896.001]
  • [Cites] Acta Cytol. 1993 May-Jun;37(3):391-6 [8388611.001]
  • [Cites] Epithelial Cell Biol. 1994 Jan;3(1):38-46 [7514934.001]
  • [Cites] Cancer Surv. 1993;18:7-34 [8013001.001]
  • [Cites] Anal Biochem. 1995 Mar 20;226(1):91-9 [7785785.001]
  • [Cites] Development. 1995 Sep;121(9):2897-908 [7555716.001]
  • [Cites] J Cell Physiol. 1997 Apr;171(1):11-9 [9119887.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1590-6 [9108465.001]
  • [Cites] Exp Cell Res. 1997 Jul 10;234(1):165-73 [9223382.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):883-8 [9816245.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1421-9 [9836473.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5466-72 [9850080.001]
  • [Cites] Exp Cell Res. 1999 Feb 25;247(1):267-78 [10047469.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):69-77 [10219907.001]
  • [Cites] Breast Cancer Res Treat. 1999 Feb;53(3):217-27 [10369068.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • (PMID = 12671707.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ PMC2376379
  •  go-up   go-down


35. Powlesland AS, Hitchen PG, Parry S, Graham SA, Barrio MM, Elola MT, Mordoh J, Dell A, Drickamer K, Taylor ME: Targeted glycoproteomic identification of cancer cell glycosylation. Glycobiology; 2009 Aug;19(8):899-909